EP0309525A1 - Determination of ions in fluids - Google Patents

Determination of ions in fluids

Info

Publication number
EP0309525A1
EP0309525A1 EP88903229A EP88903229A EP0309525A1 EP 0309525 A1 EP0309525 A1 EP 0309525A1 EP 88903229 A EP88903229 A EP 88903229A EP 88903229 A EP88903229 A EP 88903229A EP 0309525 A1 EP0309525 A1 EP 0309525A1
Authority
EP
European Patent Office
Prior art keywords
mmol
ions
enzyme
kryptofix
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP88903229A
Other languages
German (de)
French (fr)
Inventor
Michael Nathaniel Berry
Michael-Harold Town
Georg-Burkhard Kresse
Uwe Herrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flinders University of South Australia
Roche Diagnostics GmbH
Original Assignee
Flinders University of South Australia
Roche Diagnostics GmbH
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flinders University of South Australia, Roche Diagnostics GmbH, Boehringer Mannheim GmbH filed Critical Flinders University of South Australia
Publication of EP0309525A1 publication Critical patent/EP0309525A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/40—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/10—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases p-Nitrophenol derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2337/00—N-linked chromogens for determinations of peptidases and proteinases
    • C12Q2337/10—Anilides
    • C12Q2337/12—Para-Nitroanilides p-NA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding

Definitions

  • This invention is concerned with methods and reagents for the determination of ions, hereinafter also called analytes, in biological and non-biological fluids.
  • the invention is based on the ability of many analytes to stimulate or inhibit the activity of a sensitive enzyme.
  • the analytes may be cations or anions, metallic or non-metallic, simple or compound.
  • the anaiyte is present in the sample at a concentration that lies outside the range of sensitivity of the relevant analytical indicator enzyme, or that interference is caused by the presence of other ions to which the enzyme is also sensitive. This invention addresses and solves these problems in diverse ways.
  • a common method of analysing potassium and sodium in clinical biochemistry practice is flame photometry. This process depends on the principle that certain atoms when energized by heat become excited and emit light of a characteristic wavelength when returning to ground state. The intensity of the characteristic wavelength of radiant energy produced by the atoms in the flame is directly proportional to the number of atoms excited in the flame, which is directly proportional to the concentration of the substance of interest in the sample.
  • the apparatus required is complex and relatively expensive and requires the use of combustible gases.
  • ion-selective electrodes An alternative method especially for sodium, potassium and chloride makes use of ion-selective electrodes.
  • each electrode would possess a unique ion-selective property that would allow it to respond to only one ion. In practice this is not the case and interfering ions exist for all ion-selective electrodes.
  • ion-specific electrodes are not absolutely specific although generally corrections are possible.
  • the electrodes measure the potential developed in the presence of the specific ion.
  • the instrumention is relatively expensive. Neither method can be performed spectrophotometrically and the clinical need for ion measurement therefore results in a substantial increase in the complexity of commercially available clinical analysers, most of which are designed primarily for spectrophotometric assays. Both methods require a considerable degree of skill and knowledge for their successful implementation.
  • a major drawback of these methods is the use of solutions containing highly toxic substances. Some of the methods are complicated and imprecise (e.g. the titration method). Many of the reagents are unstable and calibration curves are non-linear (e. the rhodanide method). Some of these methods in addition need a pretreatment in order to eliminate interferences by the protein content of the sample.
  • Calcium is a further example of an electrolyte which is routinely determined in the clinical laboratory.
  • concentration of this metal ion in body fluids is regulated within a narrow range. Pathologically high or low concentrations can lead to life threatening disorders such as renal insufficiency, pancreatitis, tetany and congestive heart failure.
  • the method involves the use of aggressive, highly alkaline solutions and toxic substances. It is particularly prone to interference by a number of serum components such as lipids, proteins, phosphate and bilirubin and as a result does not agree well with atomic absorption and flame photometric reference methods.
  • a further disadvantage of the colorimetric procedure is that the calibration curves are non-linear and the colour is greatly dependent on temperature.
  • an enzyme-mediated assay for measuring potassium ions in tissues is described. The method employs pyruvate kinase, from rabbit muscle, which is activated by potassium ions and sodium ions, the former being about one forty-fold more effective.
  • the method may be suitable for plant material in which potassium ions are the predominant cations, but it is unsuitable for measurements in body liquids like serum which contains a thirty-fold excess of sodium ions. Therefore sodium ions cause unacceptable interference when using the enzymatic photometric technique as described by Lowry et al. to measure potassium in plasma or serum.
  • a further problem is that ammonium ions give a similar activation to potassium ions.
  • the above mentioned publication does not address or solve these critical problems in regard to the analysis of potassium ions in biological fluids such as serum, nor does it propose any method for the determination of sodium ions.
  • the invention solves the problems by a process for the determination ions (analytes) in fluids wherein the influence of these ions on the activity of an enzyme is measured.
  • a key feature of this invention is the use of selective binding agents to bring the free concentration of the analyte within the optimal range for the analytical enzyme, particularly when dilution of the fluid is not practicable.
  • An additional element of the invention is the use of competitive inhibitors of the relevant analytical enzyme in order to reduce its sensitivity to the analyte, thereby permitting measurement of the latter at a higher concentration. This is especially useful, for example, where selective binding agents are not readily available or are unacceptably expensive.
  • Another feature of the invention is that selective binding agents are employed to reduce the free concentrations of interfering ions to levels where interference is no longer significant. Use is also made of the fact that a competitive inhibitor may compete more effectively with interfering ions than with the analyte, thereby increasing the sensitivity of the enzyme to the analyte with respect to the interfering ion.
  • an important element is the choice of optimal reaction conditions, including the selection of an appropriate isoenzyme, such that the stimulatory or inhibitory effects of the analyte are substantially greater that those of the interfering ions.
  • the action of the analyte and interfering ions on the activity of the analytical enzyme should be additive so that if the concentration of interfering ions is known, the concentration of the analyte can readily be determined by difference. Where an interfering ion is known to occur at a relatively constant concentration in the fluid under analysis, allowance can be made for this by including an appropriate concentration of the interfering ion in standard (calibrating) solutions.
  • Another method for assaying such analytes is the use of a competitive binding assay where the analyte displaces another ion from a binding agent and the effects of the released ion on the activity of an appropriate enzyme is determined.
  • Enzymes which may used can be for example (Ff.J. Evans et al. Ann. Rev. Plant Physiol. 17, 47, 1966): Transferases like phosphorous-containing group-transferring transferases.
  • Sucn a transferase may be pyruvate kinase.
  • other kinases such as adenylate kinase or hexokinase, sensitive to magnesium ion or manganous ion may be employed.
  • Another transferase is acetate kinase (from E. coli).
  • Another example is pyridoxal kinase from brain which is sensitive to zinc ions.
  • Hydrolases like glycos idases, for example ⁇ - or ⁇ -D-galactosidase (from Escherichia coli), carboxypeptidase A (from bovine pancreas), collagenase (from Clostridium hystolicum), amylase (from saliva or pancreas) or phosphoglycollate phosphatase.
  • ⁇ - or ⁇ -D-galactosidase from Escherichia coli
  • carboxypeptidase A from bovine pancreas
  • collagenase from Clostridium hystolicum
  • amylase from saliva or pancreas
  • phosphoglycollate phosphatase for example ⁇ - or ⁇ -D-galactosidase (from Escherichia coli), carboxypeptidase A (from bovine pancreas), collagenase (from Clostridium hystolicum), amylase (from saliva or pan
  • peptide hydrolases such as the cysteine or thiol dependent proteinases, specific examples of which are Calpain I and II (also called calcium activated neutral protease) described by Sasaki et al. in J. Biol. Chem. 259, 12489-12494, (1984).
  • Calpain I and II also called calcium activated neutral protease
  • the latter enzymes can be isolated and purified from a variety of animal tissues such as: rat liver and kidney, human and porcine erythrocytes, bovine brain, and rabbit skeletal muscle according to the method of A. Kitahara et al., described in J. Biochem. 95, 1759-1766 (1984).
  • a further example is dipeptidyl aminopeptidase I (E.C. 3.4.14.1, Cathepsin C), J. Ken Mc Donald, Bioch. Biophys. Res. Communication 24(5), 66, 771f.
  • Another source for the enzymes are proteins obtained by gene recombination techniques.
  • Oxidoreductases like glycerol dehydrogenase (from Enterobacter aerogenes), acetaldehydrogenase (from yeast) or tyrosinase (catechol oxidase).
  • Lyases like aldolase (from yeast) or carbonic anhydrase (from bovine erythrocytes).
  • binding agents are available for the binding of analytes or interfering ions.
  • binding or masking substances are cryptands, coronands, crown ethers, podands, spherands, hemispherands, calixarens and combinations thereof, natural occurring ionophores, for example antibiotics, cyclic peptides like valinomycin, complexones and chelating agents, for example iminodiacetic acid, EDTA, nitrotriacetic acid and derivatives thereof.
  • Such compounds are described in Griffine (Merck), 1977, No.
  • chelators capable of binding multivalent ions in particular bivalent cations are ethyleneglycol-bis-(2-aminoethyl ether)-N, N, N', N'-tetraacetic acid (referred to as EGTA) and (ethylenedinitrilo) tetraacetic acid (EDTA). While many binding agents exist that can Dind multivalent ions, e.g. EDTA and its derivatives, agents which bind monovalent ions are less common. Tetraphenylboron binds potassium ions. However, a group of compounds with wider possibilities are cryptands which are examples of reagents that can selectively bind monovalent cations in aqueous solutions (R.M. Izatt et al., Chem. Reviews 85, 271-339). Special examples for cryptands are the Kryptofix® compounds of Merck-Schuchardt, for example:
  • anioncryptandes As masking compounds for the elimination of interfering anions the following classes of substances may potentially be used: anioncryptandes, heterocyclophanes, catapinands and inorganic metalcomplexes or insoluble salts. Special examples of anion complexing compounds are described in the literature, e.g. azamono- or azapolycycles, macrocyclic quarternary tetrahedron compounds, macrocyclic bis
  • binding agents are used for the following purposes:
  • An embodiment of the invention is a process, wherein the binding agent is present and forms a complex with "indicator" ions, from which complex the indicator ions are displaced stoichiometrically by the analyte ions, and wherein the influence of the displaced indicator ions on the activity of an enzyme is assayed, thereby giving an indirect measure of the concentration of analyte ions.
  • the enzyme is pyruvate kinase
  • the indicator ions are potassium
  • the binding agent is Kryptofix® 221 and the ion to be determined is sodium
  • the enzyme is a kinase
  • the indicator ion is Mg 2+
  • the binding agent is a chelating agent, e.g.
  • the ion is a metal or the enzyme is pyridoxal kinase, the indicator ion is Zn 2+ , the binding agent is Kryptofix®221, and the ion is a heavy metal; or the enzyme is ⁇ -amylase, the binding agent is Ag or Hg and the ion to be determined is chloride; or the enzyme is collagenase the binding agent is a chelating agent such as EDTA and the ion to be determined is calcium.
  • the biological fluids in which the measurement of analytes is made are blood, serum, plasma, sweat, transudates or exudates or urine for example.
  • Other examples of fluids are tap water or extracts of foodstuffs or fruits or fermented liquids such as wine.
  • Kryptofix® 221 is included, the relative sensitivity of pyruvate kinase for potassium ions with respect to sodium ions can be increased to > 500:1. Under these circumstances it is not necessary to know the sodium ion concentration to determine the plasma potassium ion concentration down to 0.05 mmol/1 (Example C).
  • Sodium ions may also be measured by means of pyruvate kinase, provided that conditions are chosen whereby the stimulation of enzyme activity by potassium ions is reduced, and a potassium ion-binding agent, e.g. Kryptofix® 222, is included in the reaction mixture (Example E).
  • a potassium ion-binding agent e.g. Kryptofix® 222
  • the sodium ions are allowed to displace potassium ions from Kryptof ⁇ x®221, the released potassium ions stimulating the activity of pyruvate kinase in proportion to the plasma sodium ion concentration (Example F).
  • compositions and reagents for the determination of ions in biological and non-biological fluids are compositions and reagents for the determination of ions in biological and non-biological fluids.
  • the reagent according to the present invention can be present in dissolved or dry form. It can be present impregnated on an appropriate carrier.
  • a diagnostic agent in the form of a test strip can be produced by impregnating a carrier material, preferably filter paper, cellulose or synthetic fibre fleece, with solutions of the necessary reagents conventionally used for the production of test strip in readily volatile solvents, such as acetone. This can take place in one or more impregnation steps.
  • the finished test papers can be used as such or stuck in known manner on to handles or preferably sealed between synthetic resins and fine meshes.
  • a fluid for example blood plasma
  • a buffered mixture containing adenosine diphosphate (ADP), phosphoenolpyruvate (PEP), reduced nicotinamide adenine dinucleotide (NADH), pyruvate kinase (PK) and lactate dehydrbgenase (LDH).
  • ADP adenosine diphosphate
  • PEP phosphoenolpyruvate
  • NADH reduced nicotinamide adenine dinucleotide
  • PK pyruvate kinase
  • LDH lactate dehydrbgenase
  • the rate of NADH oxidation is proportional to the concentration of potassium ions (see Examples A-C).
  • the rate of reaction (1) is determined by the concentration of potassium ions present in the system, and this in turn limits the rate of reaction (2).
  • the rates of these reactions can be measured.
  • a standard approach is the spectrophotometric measurement of the rate of disappearance of NADH in reaction (2).
  • NADH absorbs strongly at 340 nm, whereas NAD does ot. Accordingly, the fall in absorbance of the reaction mixture at 340 nm (or an alternative wavelength) provides a direct measure of the rate of the reaction and from this the concentration of potassium ions present in the mixture can be derived.
  • advantage can be taken of the fact that both reaction (1) and (2) consume H + , thus lowering the proton concentration of the reaction mixture.
  • the rate of fall in proton concentration can be measured with a pH meter, or by means of a titration procedure. In these latter cases the concentration of buffer employed will be much less than in the spectrophotometric technique.
  • Other equipment such as fluor imeters or luminometers can be used to monitor the activity of pyruvate kinase.
  • pyruvate associated with PK activity There are a number of other methods of detecting the accumulation of pyruvate associated with PK activity. These include any method for measuring the inorganic phosphate or oxygen consumed or the hydrogen peroxide; acetyl phosphate or carbon dioxide generated by the enzymatic action of pyruvate oxidase; the formation of the hydrazone with 2,4-dinitrophenylhydrazine; the measurement of the reactants or products of the enyzmatic action of pyruvate carboxylase; pyruvate decarboxylase or pyruvate dehydrogenase; the use of flavine coupled systems; and isotopic methods for measuring minute concentrations of substrates (M.N. Berry et al., Analytical Biochem. 118, 544-352 (1981)).
  • ammonium ions which are generally present in serum or accumulate on standing.
  • the possibilly of ammonium ion interference can be completely avoided by including ⁇ -ketoglutarate (KG) and glutamate dehydrogenase (GDH) in the reaction mixture.
  • Ammonium ions are removed in a preincubation according to the reaction: NH 4 + + KG + NADH ⁇ glutamate + NAD +
  • the coupled method employs glucose-6-phosphate dehydrogenase. Provided that the added glucose-6-P and -KG are in excess of any ammonium ions present, all ammonium ions will be removed while preserving the NADH in the reagent.
  • Typical concentration ranges of the main reagents for the enzymatic determination at 37°C of potassium ions using a 10 ul sample of plasma or serum are:
  • Serum albumin 0 g/1 to 5 g/1
  • GDH (assayed at 25 °C) 2 500 U/1 to 20 1 300 U/1
  • glycerol dehydrogenase E.C.C. Lin et al., B 235, 1820, 1960.
  • Typical concentration ranges of the main reagents for the enzymatic determination at 37° of potassium ions using glycerol dehydrogenase are:
  • Serum albumin 0 g/1 to 5 g/1
  • GDH (assayed at 25 °C) 2 500 U/1 to 20 000 U/1
  • acetaldehyde dehydrogenase Another enzyme sensitive to potassium ions is acetaldehyde dehydrogenase (S. Black, Arch. Biochem. Biophys. 34, 86, 1951). Typical concentration ranges of the main reagents for the enzymatic determination at 37oC of potassium ions using acetaldehyde dehydrogenase are:
  • Serum albumin 0 g/1 to 5 g/1
  • GDH (assayed at 25oC) 2 500 U/1 to 20 000 U/1
  • Acetaldehyde (0.02 mmol/1 to 1 mmol/1) may be substituted for glycolaldehyde.
  • Acetaldenyde dehydrogenase also exhibits esterase activity so that potassium ion concentration can be determined by monitoring the release of 4-nitropnenol from 4-nitrophenyl acetate.
  • Typical concentration ranges of the main reagents for the enzymatic determination at 57°C of potassium ions based on the esterase activity of acetaldehyde dehydrogenase are:
  • Serum albumin 0 g/ 1 to 5 g/1
  • GDH (assayed at 25°C) 2 500 U/ 1 to 20 000 U/1
  • PK is some 40-100 times more sensitive to potassium ion than it is to sodium ion, depending on incubation conditions as described above. Hence even though sodium ions occur in the plasma at a concentration some 30 times that of potassium ions, the latter can interfere with sodium ion measurement.
  • lithium ions are omitted, PK from rabbit muscle is preferred to the bacterial enzyme, and magnesium ions may be substituted for manganese.
  • the potassium ions are specifically bound with Kryptofix® 222 and the effects of sodium ions on PK activity measured directly (Example E).
  • Typical concentration ranges of the main reagents for the enzymatic determination at 37oC of sodium ions using pyruvate kinase are:
  • PK (rabbit muscle) 50 U/1 to 10 000 U/1
  • GDH (assayed at 2S°C) 2 500 U/1 to 20 000 U/1 KG (free acid) 1 mmol/1 to 10 mmol/1
  • the sodium ions are allowed to displace potassium ions from Kryptofix® 221, the released potassium ions stimulating the activity of PK to a degree dependent on the sodium ion concentration (Example F).
  • Typical concentration ranges of the main reagents for the enzymatic determination at 37°C of sodium ions using pyruvate kinase to measure the displacement of potassium ions from Kryptofix® 221 are:
  • PK (rabbit muscle) 50 U/1 to 10 000 U/1
  • Serum albumin 0 g/1 to 5 g/1
  • GDH (assayed at 25°C) 2 500 U/1 to 20 000 U/1
  • Blood plasma is incubated with a buffered mixture containing 2-nitrophenyl-ß-D-galactopyranoside (NPG) and the enzyme ß-D-galactosidase.
  • NPG 2-nitrophenyl-ß-D-galactopyranoside
  • the reaction catalysed by ß-D-galactosidase is dependent on the presence of sodium ions and the rate of activity is a measure of sodium ion concentration.
  • a key feature of this method is the use of an appropriate amount of sodium ion-selective binding agent (e.g.
  • Kryptofix® 221) for measurements in serum or other biological fluids where the sodium ion concentration may exceed 100 mmol/1, to reduce sodium ion concentration so that the enzyme is most sensitive to small changes in sodium ion concentration in the usual analytical range (110-170 mmol/1).
  • the rate of 2-nitrophenol and galactose formation is virtually proportional to the concentration of sodium ions being measured.
  • Magnesium ions are required for optimal ß-galactosidase activity. Lithium ions are competitive with sodium ions and therefore raise the Km of the enzyme for sodium ions.
  • the galactosidase-containing sample is mixed with an appropriate ß-D-galactosidase substrate, the substrate being split by the enzyme, one of the fission products then bein detected in an appropriate manner. Either the glycone liberated by action of the enzyme or the aglycone can be measured. As a rule, the latter is determined.
  • substrate the natural substrate lactose can be used, but especially advantageous is use of a chromogenic galactoside.
  • phenyl-ß-D-galactoside as well as some further derivatives substituted on the aromatic ring, for example, 2-nithophenyl-ß-D-galactoside (NPG) and 3-nitrophenyl-ß-D-galactoside, as substrates of ß-D-galactosidase.
  • NPG 2-nithophenyl-ß-D-galactoside
  • 3-nitrophenyl-ß-D-galactoside substrates of ß-D-galactosidase.
  • the phenols liberated by hydrolysis are determined photometrically in the UV range or, in the case of the nitrophenols, in the short-wave visible wavelenght range.
  • An oxidative coupling with aminoantipyrine can also follow as indicator reaction (see Analytical Biochem. 40, 281 (1971)).
  • Other substrates are described in the German Offenlegungsschrift 33 45 748 and the German Offenlegungsschrift 34 11 574.
  • Typical concentration ranges of the main reagents for the enzymatic determination at 37°C of sodium ions using a 10 ⁇ l sample of plasma or serum are:
  • EGTA Lithium salt
  • Serum albumin 0 g/1 to 5 g/1
  • EGTA means Ethylenbis (oxyethylennitrilo)-tettraacetic acid. It will also be feasible to perform the analysis of sodium and potassium ions enzymatically in the same cuvette in the form of a twin test (see Example G).
  • a sample of blood plasma (or other body fluid) is incubated with a buffered mixture containing the peptide substrate succinyl-leucine-methionine-p-nitroanilide and the enzyme Calpain I.
  • the reaction catalyzed by Calpain I is dependent on the presence of calcium ions and the rate of activity is a measure of the calcium ion concentration.
  • a key feature of the method is the use of chelators capable of specifically binding calcium ions in order to lower their concentration to a range over which the enzyme is most sensitive. Under the conditions chosen for analysis, which include the presence of L-cysteine and 2-mercaptoethanol, the rate of p-nitroaniline formation is virtually proportional to the concentration of calcium being measured.
  • Preferred peptide substrates can oe described by the general formula
  • R represents acetyl, benzoyl, carbobenzoxy, succinyl, tert-butoxy carbonyl or 3-(2-furyl)acryloyl
  • P n - P 2 - P 1 represents a peptide chain of a least 2 residues with a preference for Tyr, Met, Lys or Arg in the P 1 position and a Leu or Val residue in the P 2 position
  • X represents a chromogenic or fluorogenic group which is liberated by the action of the enzyme to yield a detectable change in colour or fluorescence.
  • X can be a nitrophenyl, naphthyl or thiobenzyl ester as well as a nitroaniline, naphthylamine or methylcoumarin group either with without further substituents on the aromatic ring.
  • concentration ranges of the compounds for such a determination method and reagents are:
  • the asterisk * means that unit is defined as the quantity of enzyme which increases the absorbance at 750 nm by 1.0 after 30 min of incubation at 30°C with casein as substrate (N. Yoshimura et al., J. Biol. Chem. 258, 8883-8889, (1985)).
  • any buffer having a pK in the required pH range with a negligible binding capacity for calcium may be used in the assay.
  • Many of the Good-type buffers such as Tris, HEPES, MOPSO, BES, TES and imidazole fulfil these requirements (see example H).
  • Collagenase may be used instead of Calpain I, and assayed fluorometricaily at pH 6.5-7.5 with L-isoleucyl-L-analyiglycyl ethylester, 0.02 mmol/1 to 0.2 mmol/1.
  • the concentration ranges of the compounds of such a determination method are:
  • Any buffer having a pK in the required pH-range and a negligible chloride concentration may be used in the assay.
  • Examples of enzymes from all of the categories listed above have been shown in the literature to have a chloride dependency, especially if the origin of these enzymes is from halophilic organisms.
  • the chloride dependency of Enzymes of the peptidase type has been extensively described. For examples dipeptidylpeptidase I (Cathepsin C), EC 3.4.14.1 (J. Ken Mc Donald, Bioch. Bioph. Res. Communication, 24 (5) 1966, 771f) or dipeptidylpeptidase III EC. 3.4.14.3 (J.
  • angiotensin converting enzyme EC 3.4.15.1 which is a dipeptidylcarboxypeptidase that catalyses the hydrolytic release of dipeptides from the carboxyl terminus of a oroad range of oligopeptides (P. Bunning et al., Bioch. 26, 1987, 3374f; R. Shapiro et al., Bioch. 22, 1983, 3850f).
  • X represents a chromogenic- or fluorogenic group which is liberated by the action of the enzyme to yield a detectable change in colour or fluorescence.
  • X can be a nitrophenyl-, naphthyl- or thiobenzylester as well as a nitroaniline, naphthylamine or methylcoumarin group either with or without further substituents on the aromatic ring.
  • R is a chromogenic or fluorogenic group which is liberated by the action of the genzyme.
  • R can be a N-2-furanacryloyl- or benzoyl-group either with or without further substituents (see example I).
  • p-nitrophenol is entirely dependent on the presence of chloride anions, once again using either predilution, small sample volumenes or selective binding agents to adjust chloride ion concentration to the optimal range of the enzyme.
  • the test principle is summarised below, and the rate of the reaction is determined by the measurement of the increase in absorption at 405 nm.
  • Hepes or alternative chloride free Duffer 0.01-0.5 mmol/1 pH 6.5-7.5 ⁇ -amylase 60-6000 U/1 ⁇ -glucosidase 3000-300 000 U/1
  • Kryptofix® 221 and Kryptofix® 222 These metals biid tightly to cryptands such as Kryptofix® 221 and Kryptofix® 222. They will therefore displace other metals that are more loosely bound.
  • An example of a metal ion readily displaced is zinc. Zinc ions are present in very low concentration in plasma. Thus it is feasible to add zinc ions complexed to K 221 to a buffered serum mixture. If a heavy metal is present the zinc ions will be liberated and their presence can be detected by stimulation of pyridoxal kinase (from sheep brain) an enzyme which is highly sensitive to zinc ions. Many other similar competitive binding assays are feasible, and those described are given by way of example and not of limitation.
  • Bicarbonate ions can be measured using a variation of the principles embodied in the invention.
  • Many ligands e.g. the cryptands, are pH sensitive, and this property can be exploited to measure bicarbonate.
  • advantage is taken of the ability of bicarbonate to neutralize protons. It can be shown that the pH of a very lightly buffered serum sample, to which hydrochloric acid has been added will vary as a function of the bicarbonate concentration. The final pH is detected by the amount of free sodium ions (as detected with ß-galactosidase) present in the presence of a pH-sensitive ion-binding agent such as Kryptof i x® 221, and this is a function of the original bicarbonate concentration.
  • a pH-sensitive ion-binding agent such as Kryptof i x® 221
  • serum is acidfied to pH 4.5 approx, with an equal volume of HCl (75 mmol/1) to convert all bicarbonate to hydroxyl ions, and then reacted with an assay system at pH 7.5-7.8, using a dilute Tris buffer (5 mmol/1) which incorporates an ion-selective enzyme, such as ß-galactosidase and appropriate pH-sensitive ion binding agent.
  • a dilute Tris buffer (5 mmol/1) which incorporates an ion-selective enzyme, such as ß-galactosidase and appropriate pH-sensitive ion binding agent.
  • the sodium ion concentration of the sample of the sample must be known to obtain accurate results since a correction is necessary based on the quantity of sodium ions in the sample.
  • the method is substantially more sensitive than procedures using chromogenic indicators as pH detectors (Example K).
  • Typical concentration ranges of the main reagents for the enzymatic determination at 37°C of bicarbonate ions using a 10 ⁇ l sample of plasma or serum are:
  • the need to correct for sodium ion concentration can be aboided by using an enzyme (e.g. pyridoxal kinase) sensitive to trace metals (e.g. zinc ions) normally present in plasma in ulcromolar concentration.
  • trace metals e.g. zinc ions
  • bicarbonate ions can be measured by including the zinc ions in the reaction mixture in concentrations sufficiently in excess of those that can be encountered in plasma. Hence endogenous zinc ions will not interfere.
  • the methods as described above are simple, very rapid, accurate and precise and can be performed with inexpensive apparatus.
  • the laboratory hazard of inflammable gases can be avoided as can the many problems associated with ion-selective electrodes.
  • the method can be adapted for use with large equipment performing multiple analyses, yet can also be employed with inexpensive stand-alone instruments for emergency use close to the bedside.
  • the packaging of the method in kit form is straightforward.
  • the determination of potassium and sodium ion concentration can be performed sequentially in the same cuvette (Example G). It is also intended that the method be useful for Doctors' offices with a machine employing dry chemistries. Although these methods have been developed using automatic spectrometers, they are readily adaptable to automated or manual laboratory equiment such as fluorimeters, luminometers, isotope counters etc.
  • the final incubation mixture contains:
  • Potassium ion standards contain 140 mmol/1 sodium ions to compensate for the stimulatory effect of sodium ions, present in plasma, on pyruvate kinase.
  • the incubation mixture and calibrating solution are the same as for Example A.
  • a correction may be made for the sodium ion concentration of the mixture by adding (or subtracting) 0.1 mmol/1 potassium for every 10 mmol/1 the sodium ion concentration is below (or above) 140 mmol/1 sodium ions. However, this correction should be verified by analysing aqueous solutions containing known sodium and potassium concentrations.
  • Example B but human serum albumin is omitted and the medium contains in addition 6 ⁇ mol of Kryptofix® 221 per assay.
  • a pH of 7.8 is selected to minimise variations in displacement of sodium ions from Kryptofix® 221 due to the differing potassium ion content of Individual specimens.
  • the reaction is monitored at 420 nm (or nearby) wavelength to determine the rate of formation of free 2-nitrophenol and hence the concentration of sodium ions in the original sample.
  • Variation b An alternative approach compared with Variation a would be to reduce the sample concentration ten-fold by pre-dilution or to use a small sample volume, in which case the cryptand could be omitted.
  • Variation c Measurement in fluids of low sodium ion content (e.g. ⁇ 20 mmol/1) in which case the cryptand could be omitted.
  • Variation a Incubation mixture contains for a 10 ul plasma sample:
  • Sodium ion calibrating solutions contain 4 mmol/1 potassium to compensate for the potassium activating effect of serum potassium ions on pyruvate kinase.
  • the final incubation mixture contains for a 10 ⁇ l plasma sample:
  • Potassium chloride is added to this reagent and displaced stoichiometrically from Kryptofix® 221 by sodium ions, thus allowing the sodium ion concentration of the specimen to be quantified.
  • Example D Sodium ion concentration is assayed first as in Example D except that the assay also contains:
  • the pH of the incubation mixture is lowered to pH 7.4 with a hydrochloric acid aliquot.
  • reaction rate may then be monitored at 340 nm but may also be measured at a slightly higher wavelength to minimise possible Interference by the 2-nitrophenol liberated in the sodium ion indicator reaction.
  • a small sample of blood is centrifuged to obtain plasma.
  • the sample was incubated with a mixture containing 50 mmol/1 imidazole-HCl buffer, pH 7.3, 5 mmol/1 L-cysteine, 2.5 mmol/1 2-mercaptoethanol, 0.1 mmol/1 EGTA and 5 mmol/1 Suc-Leu-Met-p-nitroanilide at 30°C.
  • the increase of absorbance at 405 nm was monitored over at 5 min interval. The rate is proportional to the calcium ion concentration of the sample.
  • a small sample of blood is centrifuged to obtain plasma (5 ⁇ l).
  • the incubation mixture contains 0.05 mol/1 citrate buffer pH-5.0, 10mmol/1 cysteamine and 4 mmol/1 gly-arg-p-nitroanilide and 0.01 U/ml cathepsin C.
  • the latter has been dialyzed against 10 mmol/1 sodiumphosphate buffer (pH - 6.8) and 43 % (v/v) of glycerol in order to remove chloride ions.
  • a typical calibration curve obtained this way is shown in Fig. 1.
  • Inhibition mixture contains for a 5 ul plasma sample:
  • Hepes or alternative chloride free buffer 100 mmol/1 pH 7.1 ⁇ -Amylase 600 U/1 ⁇ -Glucosidase 30 000 U/1
  • the reaction is monitored at 405 nm (or nearby wavelength to determine the rate of formation of free 4-nitrophenol and hence the concentration of chloride ions in the original sample.
  • Variaton b Pyridoxal kinase, pyridoxal and zinc ions are substituted for ß-galactosidase and NGP.

Abstract

Procédé et réactif pour effectuer un dosage ionique dans des fluides, l'influence de ces ions sur l'activité d'une enzyme étant mesurée. Les ions sont par exemple du sodium, potassium, calcium , magnésium, manganèse, lithium, plomb, zing, cuivre, fer ou d'autres métaux lourds ou bien des ions non métalliques incluant le chlorure, bicarbonate, des protons, et des substances d'ammonium donnant naissance à l'ammonium. Les enzymes qui sont utilisées peuvent être par exemple une transférase, une hydrolase, une oxydoréductase, ou une lyase. Une partie essentielle de l'invention est une méthode pour exclure les interférences dues à des ions par le masquage des ions d'interférence avec un agent de liaison.Method and reagent for carrying out an ionic assay in fluids, the influence of these ions on the activity of an enzyme being measured. The ions are for example sodium, potassium, calcium, magnesium, manganese, lithium, lead, zinc, copper, iron or other heavy metals or else non-metallic ions including chloride, bicarbonate, protons, and substances ammonium giving rise to ammonium. The enzymes which are used can be for example a transferase, a hydrolase, an oxidoreductase, or a lyase. An essential part of the invention is a method for excluding interference due to ions by masking the interference ions with a binding agent.

Description

DETERMINATION OF IONS IN FLUIDS
This invention is concerned with methods and reagents for the determination of ions, hereinafter also called analytes, in biological and non-biological fluids.
The invention is based on the ability of many analytes to stimulate or inhibit the activity of a sensitive enzyme. The analytes may be cations or anions, metallic or non-metallic, simple or compound. In practice it is frequently found that the anaiyte is present in the sample at a concentration that lies outside the range of sensitivity of the relevant analytical indicator enzyme, or that interference is caused by the presence of other ions to which the enzyme is also sensitive. This invention addresses and solves these problems in diverse ways.
In the practice of Clinical Biochemistry the measurement of ser electrolytes are the most common analytical tests performed wit hospitals. These measurements are requested not only for routine investigations but frequently for emergency and life-threatening situations where speed of analysis is essential. Since a major source of delay in hospitals is the transport of specimens from the wards to the diagnostic laboratories, a method that is easily performed near the bed-side would be of particular value in emergency situations.
A common method of analysing potassium and sodium in clinical biochemistry practice is flame photometry. This process depends on the principle that certain atoms when energized by heat become excited and emit light of a characteristic wavelength when returning to ground state. The intensity of the characteristic wavelength of radiant energy produced by the atoms in the flame is directly proportional to the number of atoms excited in the flame, which is directly proportional to the concentration of the substance of interest in the sample. The apparatus required is complex and relatively expensive and requires the use of combustible gases.
An alternative method especially for sodium, potassium and chloride makes use of ion-selective electrodes. Ideally, each electrode would possess a unique ion-selective property that would allow it to respond to only one ion. In practice this is not the case and interfering ions exist for all ion-selective electrodes. Moreover, ion-specific electrodes are not absolutely specific although generally corrections are possible. The electrodes measure the potential developed in the presence of the specific ion. The instrumention is relatively expensive. Neither method can be performed spectrophotometrically and the clinical need for ion measurement therefore results in a substantial increase in the complexity of commercially available clinical analysers, most of which are designed primarily for spectrophotometric assays. Both methods require a considerable degree of skill and knowledge for their successful implementation.
Similarily, the routine determination of chloride by coulometric methods requires special instrumentation. The endpoint of this titration procedure is detected by an increase in electrical flux completion of formation of insoluble silver chloride product. Alternatively, potentiometr ic determinations may be used which are also very time consuming and involve additional instrumentation. For chloride, in addition, there are a numoer of photometric an titrimetric methods, which e.g. include:
titrimetric determination of free Hg2+ ions via diphenylcarbazone complex
colorimetric determination of the rhodanide complex of iron wnich is formed after dissociation of the mercury complexes upon precipitation of HgCl2 (Skeggs, Clin. Chem. 10, 1964, 918f.; Schmidt, Zentralblatt Pharm. 124 (9), 1985, 527f)
colorimetric determination of chloranilic acid from the respective mercury salt (Renschler)
determination of the coloured Cu2+ complex of diethyldithiocarbaminic acid from the colourless mercury salt (German Offenlegungsschrift 2137146)
the rather common TPTZ-method (tripyridile-s-triazine) (R. Fried, Zeitschr. Klin. Chem., Klin. Bioch. 10, 1972, 280f; DOS 215 3387) which is similarily based on the formation of a coloured metal complex upon dissociation of a mercury complex.
A major drawback of these methods is the use of solutions containing highly toxic substances. Some of the methods are complicated and imprecise (e.g. the titration method). Many of the reagents are unstable and calibration curves are non-linear (e. the rhodanide method). Some of these methods in addition need a pretreatment in order to eliminate interferences by the protein content of the sample.
An improved TPTZ-method is described in Wo. 83/002670, the use of toxic mercury compounds however is still a disadvantage. The only colorimetric method without use of mercury ions is the determination of hexachlorocomplexes of Fe(III) in a perchloric acid solution (F. Hoppe., Ther. Ggw. 110(4), 1971, 554f.; H. Mahner, Zeitschr. Klin. Chem., klin. Biochem. 11(11), 1973, 451f.; W. T. Law, Clin. Chem. 26 (15) 1980, 1874f.; US-4278440). A considerable limitation of this method is the use of strongly acid reagents which are corrosive and therefore not compatible with mechanical pitetting systems. A further disadvantage is the interference by bilirubin in the samples.
Calcium is a further example of an electrolyte which is routinely determined in the clinical laboratory. The concentration of this metal ion in body fluids is regulated within a narrow range. Pathologically high or low concentrations can lead to life threatening disorders such as renal insufficiency, pancreatitis, tetany and congestive heart failure.
One of the earliest methods for the determination of calcium was that described by Tisdall (J. Biol. Chem. 63, 461-465, 1925) in which calcium is precipitated by oxalic acid which is in turn estimated colorimetrically. The method involves a centrifugation step and is therefore very time consuming; it is not specific for calcium and depends on a careful handling of samples. The method has been succeeded in many laboratories by titrimetric and direct colorimetric procedures. The former also has the drawback of a complicated and cumbersome procedure and requires large sample volumes. In the latter procedure calcium affects the colour of a dye, for example orthocresolphthalein complexone, which can be measured in a photometer. Due to the simplicity of the method it lends itself to automation in the clinical laboratory. The method, however, involves the use of aggressive, highly alkaline solutions and toxic substances. It is particularly prone to interference by a number of serum components such as lipids, proteins, phosphate and bilirubin and as a result does not agree well with atomic absorption and flame photometric reference methods. A further disadvantage of the colorimetric procedure is that the calibration curves are non-linear and the colour is greatly dependent on temperature. In W.H. Outlaw and O.H. Lowry, Analytical Biochemistry 92, 370-374 (1979) an enzyme-mediated assay for measuring potassium ions in tissues is described. The method employs pyruvate kinase, from rabbit muscle, which is activated by potassium ions and sodium ions, the former being about one forty-fold more effective. Because of this non-specificity the method may be suitable for plant material in which potassium ions are the predominant cations, but it is unsuitable for measurements in body liquids like serum which contains a thirty-fold excess of sodium ions. Therefore sodium ions cause unacceptable interference when using the enzymatic photometric technique as described by Lowry et al. to measure potassium in plasma or serum. A further problem is that ammonium ions give a similar activation to potassium ions. The above mentioned publication does not address or solve these critical problems in regard to the analysis of potassium ions in biological fluids such as serum, nor does it propose any method for the determination of sodium ions.
Therefore, it is an object of the present invention to provide a process and a reagent by which the above mentioned problems are avoided. The invention solves the problems by a process for the determination ions (analytes) in fluids wherein the influence of these ions on the activity of an enzyme is measured.
A key feature of this invention is the use of selective binding agents to bring the free concentration of the analyte within the optimal range for the analytical enzyme, particularly when dilution of the fluid is not practicable. An additional element of the invention is the use of competitive inhibitors of the relevant analytical enzyme in order to reduce its sensitivity to the analyte, thereby permitting measurement of the latter at a higher concentration. This is especially useful, for example, where selective binding agents are not readily available or are unacceptably expensive.
Another feature of the invention is that selective binding agents are employed to reduce the free concentrations of interfering ions to levels where interference is no longer significant. Use is also made of the fact that a competitive inhibitor may compete more effectively with interfering ions than with the analyte, thereby increasing the sensitivity of the enzyme to the analyte with respect to the interfering ion.
An important element is the choice of optimal reaction conditions, including the selection of an appropriate isoenzyme, such that the stimulatory or inhibitory effects of the analyte are substantially greater that those of the interfering ions. In addition, the action of the analyte and interfering ions on the activity of the analytical enzyme should be additive so that if the concentration of interfering ions is known, the concentration of the analyte can readily be determined by difference. Where an interfering ion is known to occur at a relatively constant concentration in the fluid under analysis, allowance can be made for this by including an appropriate concentration of the interfering ion in standard (calibrating) solutions. Another method for assaying such analytes is the use of a competitive binding assay where the analyte displaces another ion from a binding agent and the effects of the released ion on the activity of an appropriate enzyme is determined.
These general principles can best be illustrated in detail by showing their application to the determination of potassium, sodium, calcium, chloride and bicarbonate ions in plasma or serum. However, they are applicable to a wide spectrum of ions, for example cations such as magnesium, manganese, lithium, lead, zinc, copper, iron or other heavy metals. Examples of non-metallic ions that can be measured are protons or ammonium. Substances such as urea that give rise to ammonium can also be determined.
Suitable Enzymes
Enzymes which may used can be for example (Ff.J. Evans et al. Ann. Rev. Plant Physiol. 17, 47, 1966): Transferases like phosphorous-containing group-transferring transferases. Sucn a transferase may be pyruvate kinase. In place of pyruvate kinase other kinases such as adenylate kinase or hexokinase, sensitive to magnesium ion or manganous ion may be employed. Another transferase is acetate kinase (from E. coli). Another example is pyridoxal kinase from brain which is sensitive to zinc ions.
Hydrolases like glycos idases, for example α- or β-D-galactosidase (from Escherichia coli), carboxypeptidase A (from bovine pancreas), collagenase (from Clostridium hystolicum), amylase (from saliva or pancreas) or phosphoglycollate phosphatase.
Also peptide hydrolases such as the cysteine or thiol dependent proteinases, specific examples of which are Calpain I and II (also called calcium activated neutral protease) described by Sasaki et al. in J. Biol. Chem. 259, 12489-12494, (1984). The latter enzymes can be isolated and purified from a variety of animal tissues such as: rat liver and kidney, human and porcine erythrocytes, bovine brain, and rabbit skeletal muscle according to the method of A. Kitahara et al., described in J. Biochem. 95, 1759-1766 (1984). A further example is dipeptidyl aminopeptidase I (E.C. 3.4.14.1, Cathepsin C), J. Ken Mc Donald, Bioch. Biophys. Res. Communication 24(5), 66, 771f. Another source for the enzymes are proteins obtained by gene recombination techniques.
Oxidoreductases like glycerol dehydrogenase (from Enterobacter aerogenes), acetaldehydrogenase (from yeast) or tyrosinase (catechol oxidase).
Lyases like aldolase (from yeast) or carbonic anhydrase (from bovine erythrocytes).
Other suitable enzymes are various enzymes from halophilic organisms. Another source for the enzymes are proteins obtained by gene recombination techniques. Selective Binding Agents: A wide variety of binding agents are available for the binding of analytes or interfering ions. Such binding or masking substances are cryptands, coronands, crown ethers, podands, spherands, hemispherands, calixarens and combinations thereof, natural occurring ionophores, for example antibiotics, cyclic peptides like valinomycin, complexones and chelating agents, for example iminodiacetic acid, EDTA, nitrotriacetic acid and derivatives thereof. Such compounds are described in Kontakte (Merck), 1977, No. 1, p. 11 ff and p. 29 ff Kontakte (Merck), 1977, No. 2, p. 16 ff; Konakte (Merck), 1977, No. 3, p. 56 ff; Phase Transfer Catalysts, Properties and Applications (Merck-Schuchardt) 1987, Thermodynamic and Kinetic Data for Cation-Macrocycle Interaction; R.M. Izatt et al., Chemical Reviews 85, 271-339 (1985); Data for Biochemical Research, 1986, R.M.C. Dawson et al., Eds., 3rd edit., 399-415 (Clarendon Press) Oxford; F. Vögtle et al., Chem. Macrocycles, Springer Verlag, New York, 1985; G.W. Gokel et al., Eds., Macrocyclic Polyether Synthesis, Springer Verlag, New York, 1982; M. Hiraoka, Ed., Crown Compounds, Elsevier, Amsterdam, Oxford, Ne York, 1982; J.M. Lehn et al., J.Am. Chem. Soc. 97, 6700-6707 (1975); G. Schwarzenbach et al., Helv.Chim. Acta 28, 828 (1945); S.F.A. Kettle, Koordinationsverbindungen, Taschentext 3, Verlag Chemie, Weinheim/Bergstr. 1972; A.E. Martell et al., Die Chemie der Metallchelatverbindungen, Verlag Chemie, Weinheim/Bergstr. 1958; M. Becke-Goehring et al., Komplexchemie, Springer Verlag, 1970; F. Kober, Grundlagen der Komplexchemie, Otto Salle Verlag, Frankfurt/Main 1979; G. Schwarzenbach et al., Helv.Chim.Acta 31, 1029 (1948); R.G. Pearson et al., Science 151, 172 (1966).
Examples of chelators capable of binding multivalent ions, in particular bivalent cations are ethyleneglycol-bis-(2-aminoethyl ether)-N, N, N', N'-tetraacetic acid (referred to as EGTA) and (ethylenedinitrilo) tetraacetic acid (EDTA). While many binding agents exist that can Dind multivalent ions, e.g. EDTA and its derivatives, agents which bind monovalent ions are less common. Tetraphenylboron binds potassium ions. However, a group of compounds with wider possibilities are cryptands which are examples of reagents that can selectively bind monovalent cations in aqueous solutions (R.M. Izatt et al., Chem. Reviews 85, 271-339). Special examples for cryptands are the Kryptofix® compounds of Merck-Schuchardt, for example:
4,7, 13, 16, 21-Pentaoxa-1,10-diazabicyclo[8.8.5]-tricosan, Kryptofix® 221, page 438, Merck-Schuchardt catalogue, dated 1987/88, no. 810646 (K 221).
4, 7, 13, 16, 21,24-Hexaoxa-1,10-diazabicyclo[8.8.8] hexacosan, Kryptofix® 222, page 438, Merck-Schuchardt catalogue, dated 1987/1988, no. 810647 (K 222).
As masking compounds for the elimination of interfering anions the following classes of substances may potentially be used: anioncryptandes, heterocyclophanes, catapinands and inorganic metalcomplexes or insoluble salts. Special examples of anion complexing compounds are described in the literature, e.g. azamono- or azapolycycles, macrocyclic quarternary tetrahedron compounds, macrocyclic bis -metal-complexes, macrocycles with covalently incorporated lewis acid centers, protonated- or alkylated quarternary cryptands or catapinands (F. P. Schmidtchen, Nachrichten Chem. Techn. lab. 36(1), 1988, S. 8f; E. Graf, J. Amer. Chem. Soc. 98 (20), 1976, 6403f; C. H. Park, J. Amer. Chem. Soc. 90 (9), 1968, 2431f) as well as e.g. the hexachloro complex of Fe (III) or silver nitrate.
Function of Binding Agents: These binding agents are used for the following purposes:
1. The selectivce binding of interfering ions. 2. To reduce the concentration of the analytes to optimal measuring levels, if dilution of the sample is not feasible.
3. An embodiment of the invention is a process, wherein the binding agent is present and forms a complex with "indicator" ions, from which complex the indicator ions are displaced stoichiometrically by the analyte ions, and wherein the influence of the displaced indicator ions on the activity of an enzyme is assayed, thereby giving an indirect measure of the concentration of analyte ions. For example in such a process the enzyme is pyruvate kinase, the indicator ions are potassium, the binding agent is Kryptofix® 221 and the ion to be determined is sodium; or the enzyme is a kinase, the indicator ion is Mg2+, the binding agent is a chelating agent, e.g. EDTA, and the ion is a metal or the enzyme is pyridoxal kinase, the indicator ion is Zn2+, the binding agent is Kryptofix®221, and the ion is a heavy metal; or the enzyme is α-amylase, the binding agent is Ag or Hg and the ion to be determined is chloride; or the enzyme is collagenase the binding agent is a chelating agent such as EDTA and the ion to be determined is calcium.
Fluids for Analysis: The biological fluids in which the measurement of analytes is made are blood, serum, plasma, sweat, transudates or exudates or urine for example. Other examples of fluids are tap water or extracts of foodstuffs or fruits or fermented liquids such as wine.
Application of General Principles to the Determination of Potassium and Sodium Ions
The essential requirements for a satisfactory method for the determination of potassium Ions in serum or plasma, on the basis of the sensitivity of pyruvate kinase to potassium ions, is the overcoming of the interference by sodium and ammonium ions. According to the general principles embodied in this invention this can be achieved by one or more of the following procedures:
1. The selective binding of sodium ions with a suitable binding agent, for example Kryptofix® 221.
2. The selection of Bacillus stearothermophilus, rather than rabbit muscle, as the source of pyruvate kinase since the bacterial enzyme has a sensitivity for potassium ions in relation to sodium ions twice as great as the muscle enzyme.
5. Inclusion of ions which are competitive inhibitors of the sensitive indicator enzyme in the assay, for example the use of lithium ions to compete with sodium ions and potassium ions.
4. Enzymatic removal of ammonium ions.
Since lithium ions are less effective as a competitor against potassium ions, the net effect is to increase the relative sensitivity of pyruvate kinase towards potassium ions a further 50 % as compared with sodium ions. Moreover, in the presence of lithium ions the effects of potassium and sodium ions on the activity of pyruvate kinase become additive, rather than co-operative. This allows the possibility of mesurement of the concentration of either potassium or sodium ions, provided that the concentration of the other ions is known.
By the use of procedure 2 and 3 in the absence of a binding agent it is possible to obtain a relative sensitivity of pyruvate kinase for potassium versus sodium ions in the order of 100:1. This means that even at extremely abnormal sodium ion concentrations of either 110 or 170 mmol/1, the error in measured potassium ion concentration will not exceed 0.3 mmol/1 relative to a normal plasma sodium ion concentration of 140 mmol/1 (Example A). This is not regarded as sufficiently accurate for many clinical purposes. However, if the true concentration of sodium ions in the plasma is known, accurate measurement of potassium ions down to ± 0.05 mmol/1 is feasible (Example B). If procedure 1-3 are combined and a binding agent, e.g. Kryptofix® 221 is included, the relative sensitivity of pyruvate kinase for potassium ions with respect to sodium ions can be increased to > 500:1. Under these circumstances it is not necessary to know the sodium ion concentration to determine the plasma potassium ion concentration down to 0.05 mmol/1 (Example C).
These methods for potassium ion determination demonstrate the applicability of the general principles embodied in the invention in regard to reduction of interferences. On the other hand the measurement of sodium ions in serum or plasma best illustrates the application of these principles in regulating effective analyte concentration. One means of measuring sodium ions as embodied in this invention is to use an enzyme whose activity is sensitive to sodium ions. An example of such an enzyme is ß-galactosidase (Kuby et al., J. Am. Chem. Soc. 75, 890, 1953). However, the range of sodium ion concentration to which this enzyme is most sensitive is much lower than can conveniently be obtained in a plasma sample, without a dilution step.
In keeping with the principles embodied in this invention the following procedures are employed to lower the effective sodium ion concentration to optimal levels when dilution of the sample is not feasible.
1. Use of a sodium ion binding agent such as Kryptofix® 221.
2. Use of lithium ions as a competitive inhibitor of ß-galactosidase, thereby decreasing the sensitivity of the enzyme to sodium ions. The combination of procedures 1 and 2 readily allows the determination of sodium ions in plasma or serum, using ß-galactosidase, and the amount of binding aget can be manipulated to minimise the signal for sodium ion concentrations below 110 mmol/1 while enhancing the signal in the usual analytical range (110-170 mmol/1) (Example D).
Sodium ions may also be measured by means of pyruvate kinase, provided that conditions are chosen whereby the stimulation of enzyme activity by potassium ions is reduced, and a potassium ion-binding agent, e.g. Kryptofix® 222, is included in the reaction mixture (Example E).
In another method of determining plasma sodium ion concentration, the sodium ions are allowed to displace potassium ions from Kryptofιx®221, the released potassium ions stimulating the activity of pyruvate kinase in proportion to the plasma sodium ion concentration (Example F).
Other embodiments of the invention are compositions and reagents for the determination of ions in biological and non-biological fluids.
The reagent according to the present invention can be present in dissolved or dry form. It can be present impregnated on an appropriate carrier. A diagnostic agent in the form of a test strip can be produced by impregnating a carrier material, preferably filter paper, cellulose or synthetic fibre fleece, with solutions of the necessary reagents conventionally used for the production of test strip in readily volatile solvents, such as acetone. This can take place in one or more impregnation steps. The finished test papers can be used as such or stuck in known manner on to handles or preferably sealed between synthetic resins and fine meshes. The embodiments of the invention are described hereunder in some detail but it will be seen that the invention need not necessarily be limited in any one or in a combination of the details described, and in particular, mechanical or chemical variations can be utilized besides those described in this embodiment.
Detailed Description of Analytical Methods for Potassium Ions
This section describes in more detail methods for potassium ion determination embodying the principles described in this invention. For the determination of potassium ions, a fluid, for example blood plasma, is incubated with a buffered mixture containing adenosine diphosphate (ADP), phosphoenolpyruvate (PEP), reduced nicotinamide adenine dinucleotide (NADH), pyruvate kinase (PK) and lactate dehydrbgenase (LDH). The formation of pyruvate, and subsequently lactate in this mixture, in reactions catalysed by PK and LDH, is entirely dependent on the presence of appropriate cations, in the absence of which PK is virtually inactive. NADH absorbs strongly at 340 nm, whereas NAD does not.
Under the conditions chosen for analysis which include the presence of manganese ions which are required by the bacterial PK, the rate of NADH oxidation is proportional to the concentration of potassium ions (see Examples A-C).
Under these conditions the following reactions take place:
The rate of reaction (1) is determined by the concentration of potassium ions present in the system, and this in turn limits the rate of reaction (2). There are several ways in which the rates of these reactions can be measured. A standard approach is the spectrophotometric measurement of the rate of disappearance of NADH in reaction (2). NADH absorbs strongly at 340 nm, whereas NAD does ot. Accordingly, the fall in absorbance of the reaction mixture at 340 nm (or an alternative wavelength) provides a direct measure of the rate of the reaction and from this the concentration of potassium ions present in the mixture can be derived. Alternatively, advantage can be taken of the fact that both reaction (1) and (2) consume H+, thus lowering the proton concentration of the reaction mixture. The rate of fall in proton concentration can be measured with a pH meter, or by means of a titration procedure. In these latter cases the concentration of buffer employed will be much less than in the spectrophotometric technique. Other equipment such as fluor imeters or luminometers can be used to monitor the activity of pyruvate kinase.
There are a number of other methods of detecting the accumulation of pyruvate associated with PK activity. These include any method for measuring the inorganic phosphate or oxygen consumed or the hydrogen peroxide; acetyl phosphate or carbon dioxide generated by the enzymatic action of pyruvate oxidase; the formation of the hydrazone with 2,4-dinitrophenylhydrazine; the measurement of the reactants or products of the enyzmatic action of pyruvate carboxylase; pyruvate decarboxylase or pyruvate dehydrogenase; the use of flavine coupled systems; and isotopic methods for measuring minute concentrations of substrates (M.N. Berry et al., Analytical Biochem. 118, 544-352 (1981)).
In a survey of 200 serum samples good agreement has been obtained with other methods such as flame photometric or ion-selective electrode measurements. A significant interference with the method is ammonium ions which are generally present in serum or accumulate on standing. The possibilly of ammonium ion interference can be completely avoided by including α-ketoglutarate (KG) and glutamate dehydrogenase (GDH) in the reaction mixture. Ammonium ions are removed in a preincubation according to the reaction: NH4 + + KG + NADH → glutamate + NAD+
In solutions such as urine in which the ammonium ion content may be high a coupled reaction can be used.:
NH4 + + KG + NADPH → glutamate + NADP
glucose-6-P + NADP → 6-phosphogluconate + NADPH
The coupled method employs glucose-6-phosphate dehydrogenase. Provided that the added glucose-6-P and -KG are in excess of any ammonium ions present, all ammonium ions will be removed while preserving the NADH in the reagent.
Typical concentration ranges of the main reagents for the enzymatic determination at 37°C of potassium ions using a 10 ul sample of plasma or serum are:
PK (B. stearothermophilus 50 U/1 to 10 1 300 U/1
PEP (neutralized Tris salt) 0.3 mmol/1 to 30 mmol/1
Kryptofix® 221 0 mmol/1 to 30 mmol/1
NADH 0.01 mmol/1 to 0.8 mmol/1 buffer, pH 7-8 50 mmol/1 to 500 mmol/1
Mn2+ or Mg2 + 1 mmol/1 to 10 mmol/1
LiCl 2 mmol/1 to 100 mmol/1
ADP (free acid) 0.5 mmol/1 to 10 mmol/1
LDH (assayed at 25 °C) 5 000 U/1 to 100 000 U/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25 °C) 2 500 U/1 to 20 1 300 U/1
KG (free acid) 1 mmol/1 to 10 mmol/1 Another example sensitive to potassium ions is glycerol dehydrogenase (E.C.C. Lin et al., B 235, 1820, 1960). Typical concentration ranges of the main reagents for the enzymatic determination at 37° of potassium ions using glycerol dehydrogenase are:
Glycerol dehydrogenase 50 U/1 to 1000 U/1
Glycerol 0.3 mol/1 to 3 mol/1
Kryptofix® 221 0 mmol/1 to 50 mmol/1
NAD 0.1 mmol/1 to 5.0 mmol/1 buffer, pH 9 20 mmol/1 to 500 mmol/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25 °C) 2 500 U/1 to 20 000 U/1
KG (free acid) 1 mmol/1 to 10 mmol/1
Another enzyme sensitive to potassium ions is acetaldehyde dehydrogenase (S. Black, Arch. Biochem. Biophys. 34, 86, 1951). Typical concentration ranges of the main reagents for the enzymatic determination at 37ºC of potassium ions using acetaldehyde dehydrogenase are:
Acetaldehyde dehydirogenase 50 U/1 to 10 000 U/1
Glycolaldehyde 0.3 mmol/1 to 30 mmol/1 Kryptofix® 221 0 mmol/1 to 50 mmol/1
NAD 0.05 mmol/1 to 2.0 mmol/1 buffer, pH 7-8 50 mmol/1 to 500 mmol/1
Dithiothreitol 0.1 mmol/1 to 2 mmol/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25ºC) 2 500 U/1 to 20 000 U/1
KG (free acid) 1 mmol/1 to 10 mmol/1
Acetaldehyde (0.02 mmol/1 to 1 mmol/1) may be substituted for glycolaldehyde. Acetaldenyde dehydrogenase also exhibits esterase activity so that potassium ion concentration can be determined by monitoring the release of 4-nitropnenol from 4-nitrophenyl acetate. Typical concentration ranges of the main reagents for the enzymatic determination at 57°C of potassium ions based on the esterase activity of acetaldehyde dehydrogenase are:
Acetaldehyde dehydrogenase 50 U/ 1 to 10 000 U/1
4-nitrophenyl acetate 0 . 1 mmo l/ 1 t o 2 mmol/1
Kryptofix® 221 0 mmo l/ 1 to 30 mmol/1
NADH 0 .001 mmo l/ 1 to 0.1 mmol/1 buffer, pH 7-8 50 mmol/ 1 to 500 mmol/1
Dithiothreitol 0 . 1 mmol/ 1 to 2.0 mmol/1
Serum albumin 0 g/ 1 to 5 g/1
GDH (assayed at 25°C) 2 500 U/ 1 to 20 000 U/1
KG (free acid) 1 mmol/ 1 to 10 mmol/1
Determination of Sodium Ions
In principle the measurement of sodium ions, using PK, is similar to that of potassium ions, However, certain key differences exist. In the first instance PK is some 40-100 times more sensitive to potassium ion than it is to sodium ion, depending on incubation conditions as described above. Hence even though sodium ions occur in the plasma at a concentration some 30 times that of potassium ions, the latter can interfere with sodium ion measurement.
According to the general principles espoused in this invention, lithium ions are omitted, PK from rabbit muscle is preferred to the bacterial enzyme, and magnesium ions may be substituted for manganese. In one method the potassium ions are specifically bound with Kryptofix® 222 and the effects of sodium ions on PK activity measured directly (Example E). Typical concentration ranges of the main reagents for the enzymatic determination at 37ºC of sodium ions using pyruvate kinase are:
PK (rabbit muscle) 50 U/1 to 10 000 U/1
PEP (neutralized Tris salt) 0.5 mmol/1 to 30 mmol/1
Kryptofix® 222 0.4 mmol/1 to 4 mmol/1
NADH 0.01 mmol/1 to 0.8 mmol/1 buffer, pH 7-9 50 mmol/1 to 500 mmol/1
Mg2+ 1 mmol/1 to 10 mmol/1
ADP (free acid) 0.5 mmol/1 to 10 mmol/1
LDH (assayed at 25°C) 5 000 mmol/1 to 100 000 U/1 Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 2S°C) 2 500 U/1 to 20 000 U/1 KG (free acid) 1 mmol/1 to 10 mmol/1
In another method the sodium ions are allowed to displace potassium ions from Kryptofix® 221, the released potassium ions stimulating the activity of PK to a degree dependent on the sodium ion concentration (Example F).
Typical concentration ranges of the main reagents for the enzymatic determination at 37°C of sodium ions using pyruvate kinase to measure the displacement of potassium ions from Kryptofix® 221 are:
PK (rabbit muscle) 50 U/1 to 10 000 U/1
PEP (neutralized Tris salt) 0.3 mmol/1 to 30 mmol/1
Kryptofix® 221 1 mmol/1 to 10 mmol/1
NADH 0.01 mmol/1 to 0.8 mmol/1 buffer, pH 9-10 50 mmol/1 to 500 mmol/1
Mg2+ 1 mmol/1 to 10 mmol/1
ADP (free acid) 0.5 mmol/1 to 10 mmol/1
LDH (assayed at 25°C) 5 000 mmol/1 to 100 000 U/1
KCl 2 mmol/1 to 10 mmol/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25°C) 2 500 U/1 to 20 000 U/1
KG (free acid) 1 mmol/1 to 10 mmol/1 A more accurate and precise embodiment for determining uses a sodium ion dependent enzyme such as ß-galactosidase. (Example D).
Blood plasma is incubated with a buffered mixture containing 2-nitrophenyl-ß-D-galactopyranoside (NPG) and the enzyme ß-D-galactosidase. The reaction catalysed by ß-D-galactosidase is dependent on the presence of sodium ions and the rate of activity is a measure of sodium ion concentration. A key feature of this method is the use of an appropriate amount of sodium ion-selective binding agent (e.g. Kryptofix® 221) for measurements in serum or other biological fluids where the sodium ion concentration may exceed 100 mmol/1, to reduce sodium ion concentration so that the enzyme is most sensitive to small changes in sodium ion concentration in the usual analytical range (110-170 mmol/1). Under the conditions chosen for analysis, which include the presence of moderately high concentrations of magnesium and lithium ions, the rate of 2-nitrophenol and galactose formation is virtually proportional to the concentration of sodium ions being measured. Magnesium ions are required for optimal ß-galactosidase activity. Lithium ions are competitive with sodium ions and therefore raise the Km of the enzyme for sodium ions.
As subtrate for ß-D-galactosidase many other compounds are suitable. Quite generally, the galactosidase-containing sample is mixed with an appropriate ß-D-galactosidase substrate, the substrate being split by the enzyme, one of the fission products then bein detected in an appropriate manner. Either the glycone liberated by action of the enzyme or the aglycone can be measured. As a rule, the latter is determined. As substrate, the natural substrate lactose can be used, but especially advantageous is use of a chromogenic galactoside. Thus, in Biochem. Z., 333, 209 (1960), there are described phenyl-ß-D-galactoside, as well as some further derivatives substituted on the aromatic ring, for example, 2-nithophenyl-ß-D-galactoside (NPG) and 3-nitrophenyl-ß-D-galactoside, as substrates of ß-D-galactosidase. The phenols liberated by hydrolysis are determined photometrically in the UV range or, in the case of the nitrophenols, in the short-wave visible wavelenght range. An oxidative coupling with aminoantipyrine can also follow as indicator reaction (see Analytical Biochem. 40, 281 (1971)). Other substrates are described in the German Offenlegungsschrift 33 45 748 and the German Offenlegungsschrift 34 11 574.
Typical concentration ranges of the main reagents for the enzymatic determination at 37°C of sodium ions using a 10 μl sample of plasma or serum are:
ß-D-galactosidase 25 U/1 to 7500 U/1
NPG 0.25 mmol/1 to 5 mmol/1
Kryptofix® 221 0 mmol/1 to 10 mmol/1 buffer, pH 7-9.5 200 mmol/1 to 500 mmol/1 Mg2 + 0.01 mmol/1 to 10 mmol/1
EGTA (Lithium salt) 0 mmol/1 to 20 mmol/1
Serum albumin 0 g/1 to 5 g/1
EGTA means Ethylenbis (oxyethylennitrilo)-tettraacetic acid. It will also be feasible to perform the analysis of sodium and potassium ions enzymatically in the same cuvette in the form of a twin test (see Example G).
Determination of Calcium Ions
For the measurement of calcium ions, a sample of blood plasma (or other body fluid) is incubated with a buffered mixture containing the peptide substrate succinyl-leucine-methionine-p-nitroanilide and the enzyme Calpain I. The reaction catalyzed by Calpain I is dependent on the presence of calcium ions and the rate of activity is a measure of the calcium ion concentration. A key feature of the method is the use of chelators capable of specifically binding calcium ions in order to lower their concentration to a range over which the enzyme is most sensitive. Under the conditions chosen for analysis, which include the presence of L-cysteine and 2-mercaptoethanol, the rate of p-nitroaniline formation is virtually proportional to the concentration of calcium being measured.
Preferred peptide substrates can oe described by the general formula
R - Pn - P2 - P1 - X
whereby R represents acetyl, benzoyl, carbobenzoxy, succinyl, tert-butoxy carbonyl or 3-(2-furyl)acryloyl; Pn - P2 - P1 represents a peptide chain of a least 2 residues with a preference for Tyr, Met, Lys or Arg in the P1 position and a Leu or Val residue in the P2 position; and X represents a chromogenic or fluorogenic group which is liberated by the action of the enzyme to yield a detectable change in colour or fluorescence. X can be a nitrophenyl, naphthyl or thiobenzyl ester as well as a nitroaniline, naphthylamine or methylcoumarin group either with without further substituents on the aromatic ring. Some suitable peptide derivatives have also been described by T. Sasaki et al. in J. Biol. Chem. 259, 12489-12494, examples are succinyl-Leu-Met-MCA (MCA = 4-methylcoumarin-7-amide), succinyl-Leu-Tyr-MCA, succinyi-Leu-Leu-Val-Tyr-MCA and tert-butoxy carbonyl-Val-Leu-Lys-MCA. Further synthetic substrates are described in Bergmeyer HU (Ed) Methods of Enzymatic Analysis, 3rd Edition, Volume 5, p. 84-85 (1984).
The concentration ranges of the compounds for such a determination method and reagents are:
Calpain I 1 000 U/ 1 to 40 000 U/ 1*
Suc-Leu-Met-p-nitroanilide 1 mmol/ 1 to 20 mmol/ 1
Chelator 0 .0 1 mmo l/ 1 to 1 mmol/ 1
L-Cysteine 1 mmol/ 1 to 10 mmol/ 1
2-Mercaptoethanol 1 mmol/ 1 to 10 mmol/ 1
Buffer Imidazole-HCl 10 mmol/ 1 to 100 mmo l/ 1 pH 6 - 8 (preferred range 7-7.5) The asterisk * means that unit is defined as the quantity of enzyme which increases the absorbance at 750 nm by 1.0 after 30 min of incubation at 30°C with casein as substrate (N. Yoshimura et al., J. Biol. Chem. 258, 8883-8889, (1985)).
Any buffer having a pK in the required pH range with a negligible binding capacity for calcium may be used in the assay. Many of the Good-type buffers (N.E. Good et al., Biochem. 5, 467-477 (1966)) such as Tris, HEPES, MOPSO, BES, TES and imidazole fulfil these requirements (see example H). Collagenase may be used instead of Calpain I, and assayed fluorometricaily at pH 6.5-7.5 with L-isoleucyl-L-analyiglycyl ethylester, 0.02 mmol/1 to 0.2 mmol/1.
Determination of Chloride Ions
For the determination of chloride in blood, plasma is incubated with a buffered mixture containing 0.01 mol/1 cysteamine, 4 mmol/1 Gly-Phe-p-nitroanilide and 0.02 U/ml Cathepsin C. The formation p-nitroaniline is entirely dependent on the presence of the chloride anions. Selective binding agents may be added in addition in order to eliminate interference by bromide ions or to decrease the activity of chloride ions so as to adjust their concentration to the optimal range of the enzyme. Under the conditions chosen for analysis (see example 5) the rate of formation of p-nitroaniline:
is proportional to the concentration of chloride ions in the sample. In this example the rate of the reaction is determined by measurement of the increase of absorption at 405 nm. The concentration ranges of the compounds of such a determination method are:
citrate buffer 0.01 - 0.2 mol/1 pH 4 - 7 (preferred: 5.0 - 5.5) cys teamine 1 - 20 mmol/1 gly- arg-p-ni troanil ide 1 - 20 mmol/1 catheps in C 2 - 100 mU/m1
Any buffer having a pK in the required pH-range and a negligible chloride concentration may be used in the assay. Examples of enzymes from all of the categories listed above (transferases, hydrolases, oxidoreductases and lyases) have been shown in the literature to have a chloride dependency, especially if the origin of these enzymes is from halophilic organisms. The chloride dependency of Enzymes of the peptidase type has been extensively described. For examples dipeptidylpeptidase I (Cathepsin C), EC 3.4.14.1 (J. Ken Mc Donald, Bioch. Bioph. Res. Communication, 24 (5) 1966, 771f) or dipeptidylpeptidase III EC. 3.4.14.3 (J. Ken Mc Donald, Journal of Biol. Chem. 241 (7) 1966, 1494f), both catalyzing the hydrolysis of oligopeptide derivatives from the amino terminal end. Another example is the angiotensin converting enzyme EC 3.4.15.1 which is a dipeptidylcarboxypeptidase that catalyses the hydrolytic release of dipeptides from the carboxyl terminus of a oroad range of oligopeptides (P. Bunning et al., Bioch. 26, 1987, 3374f; R. Shapiro et al., Bioch. 22, 1983, 3850f).
Instead of Gly-Arg-p-nitroanilide different other dipeptide- or oligopeptide substrates may be used. Preferred peptide substrates can be described by the general formula
R-Pn-P1-X
whereby for the dipeptidyl peptidase enzymes R = H and Pn - P1 represents a peptide chain of at least 2 residues. X represents a chromogenic- or fluorogenic group which is liberated by the action of the enzyme to yield a detectable change in colour or fluorescence. X can be a nitrophenyl-, naphthyl- or thiobenzylester as well as a nitroaniline, naphthylamine or methylcoumarin group either with or without further substituents on the aromatic ring. In the case of dipetidylcarboxypeptidase enzymes X represents the amino terminal and of the peptide chain an R is a chromogenic or fluorogenic group which is liberated by the action of the genzyme. R can be a N-2-furanacryloyl- or benzoyl-group either with or without further substituents (see example I).
As a further example of the enzymatic determination of chloride ione (Example J), plasma is incubated with a buffered mixture containing 4,6-ethylidene(G7)-p-nitrophenyl (G1)- ,D-maltoheptaoside (4,6-ethylidene-G7PNP) (5 mmol/1), α-amylase (0.60 U/ml) and α-glucosidase (= 30 U/ml). The formation of p-nitrophenol is entirely dependent on the presence of chloride anions, once again using either predilution, small sample volumenes or selective binding agents to adjust chloride ion concentration to the optimal range of the enzyme. The test principle is summarised below, and the rate of the reaction is determined by the measurement of the increase in absorption at 405 nm.
2 ethylidene-G5 + 2 G2PNP + 2 ethylidene-G4 + 2 G3PNP + ethylidene-G3 + G4PNP (PNP = p-nitrophenol; G = glucose). The concentration ranges of compounds used for such a determination are:
Hepes or alternative chloride free Duffer 0.01-0.5 mmol/1 pH 6.5-7.5 α-amylase 60-6000 U/1 α-glucosidase 3000-300 000 U/1
4,6-ethylidene-G7PNP 0.5-10 mmol/1
Assay variations discussed above for Cathepsin C (Example I) also apply to Example J.
Determination of Heavy Metal Ions
These metals biid tightly to cryptands such as Kryptofix® 221 and Kryptofix® 222. They will therefore displace other metals that are more loosely bound. An example of a metal ion readily displaced is zinc. Zinc ions are present in very low concentration in plasma. Thus it is feasible to add zinc ions complexed to K 221 to a buffered serum mixture. If a heavy metal is present the zinc ions will be liberated and their presence can be detected by stimulation of pyridoxal kinase (from sheep brain) an enzyme which is highly sensitive to zinc ions. Many other similar competitive binding assays are feasible, and those described are given by way of example and not of limitation.
Determination of Bicarbonate Ions
Bicarbonate ions can be measured using a variation of the principles embodied in the invention. Many ligands, e.g. the cryptands, are pH sensitive, and this property can be exploited to measure bicarbonate. Essentially, advantage is taken of the ability of bicarbonate to neutralize protons. It can be shown that the pH of a very lightly buffered serum sample, to which hydrochloric acid has been added will vary as a function of the bicarbonate concentration. The final pH is detected by the amount of free sodium ions (as detected with ß-galactosidase) present in the presence of a pH-sensitive ion-binding agent such as Kryptof i x® 221, and this is a function of the original bicarbonate concentration. In essence, serum is acidfied to pH 4.5 approx, with an equal volume of HCl (75 mmol/1) to convert all bicarbonate to hydroxyl ions, and then reacted with an assay system at pH 7.5-7.8, using a dilute Tris buffer (5 mmol/1) which incorporates an ion-selective enzyme, such as ß-galactosidase and appropriate pH-sensitive ion binding agent. The sodium ion concentration of the sample of the sample must be known to obtain accurate results since a correction is necessary based on the quantity of sodium ions in the sample. The method is substantially more sensitive than procedures using chromogenic indicators as pH detectors (Example K).
Typical concentration ranges of the main reagents for the enzymatic determination at 37°C of bicarbonate ions using a 10 μl sample of plasma or serum are:
ß-D-galactosidase 250 U/1 to 7 500 U/1 NPG 0.25 mmol/1 to 5 mmol/1
Kryptofix® 221 0.2 mmol/1 to 5 mmol/1 Duffer, pH 7.5-7.8 1 mmol/1 to 10 mmol/1
Mg2+ 0.01 mmol/1 to 10 mmol/1
EGTA (Li salt) 0.1 mmol/1 to 5 mmol/1
Serum albumin o g/1 to 5 g/1
The need to correct for sodium ion concentration can be aboided by using an enzyme (e.g. pyridoxal kinase) sensitive to trace metals (e.g. zinc ions) normally present in plasma in ulcromolar concentration. Provided that the binding of the trace metal to its binding agent is pH sensitive and possesses a similar affinity to sodium ions for Kryptofix® 221, bicarbonate ions can be measured by including the zinc ions in the reaction mixture in concentrations sufficiently in excess of those that can be encountered in plasma. Hence endogenous zinc ions will not interfere.
The methods as described above are simple, very rapid, accurate and precise and can be performed with inexpensive apparatus. The laboratory hazard of inflammable gases can be avoided as can the many problems associated with ion-selective electrodes. The method can be adapted for use with large equipment performing multiple analyses, yet can also be employed with inexpensive stand-alone instruments for emergency use close to the bedside. The packaging of the method in kit form is straightforward. Moreover, the determination of potassium and sodium ion concentration can be performed sequentially in the same cuvette (Example G). It is also intended that the method be useful for Doctors' offices with a machine employing dry chemistries. Although these methods have been developed using automatic spectrometers, they are readily adaptable to automated or manual laboratory equiment such as fluorimeters, luminometers, isotope counters etc.
The present invention will now be described in more detail with reference to the following examples, on the basis of a serum or plasma sample of 10 μl. These examples are given by way of illustration and not of limitation.
In the following Examples a small volume of sample (10 μl except where otherwise indicated in the case of serum or plasma) is mixed with Reagent 1, containing buffered substrate and certain cofactors, and incubated for a period of time, generally 0.1-5 min. Absorbance readings are normally taken at regular intervals during this Incubation period. Reagent 2, containing the indicator enzyme is then added and the reaction rate monitored. In some Examples, Reagent 1 contains the indicator enzyme and Reagent 2 the appropriate substrate. The Examples show the final reaction mixture after the sample, Reagent 1 and Reagent 2 have been mixed. Example A
Measurement of Potassium Ion Concentration Using Pyruvate Kinase without a Sodium-Ion-Binding Agent, Sodium Ion Concentration Unknown.
The final incubation mixture contains:
175 mmol/1 Tris-HCl buffer, pH 7.4 20 mmol/1 Li+ [17 mmol/1 LiOH, 5 mmol/1 LiCl] 3.0 mmol/1 MnCl2 2.6 mmol/1 ADP (free acid) 2.9 mmol/1 PEP (neutralized tris salt) 0.4 mmol/1 NADH 17000 U/1 LDH (assayed at 25°C) 890 U/1 PK from Bacillus stearothermophilus 4.0 mmol/1 KG 8600 U/1 GDH (in glycerol; assayed at 25°C) 140 mg/1 Human serum albumin
Potassium ion standards (calibrating solutions) contain 140 mmol/1 sodium ions to compensate for the stimulatory effect of sodium ions, present in plasma, on pyruvate kinase.
Example B
Measurement of Potassium Ion Concentration Using Pyruvate Kinase, without a Sodium Ion Binding Agent, Sodium Ion Concentration Known.
The incubation mixture and calibrating solution are the same as for Example A.
A correction may be made for the sodium ion concentration of the mixture by adding (or subtracting) 0.1 mmol/1 potassium for every 10 mmol/1 the sodium ion concentration is below (or above) 140 mmol/1 sodium ions. However, this correction should be verified by analysing aqueous solutions containing known sodium and potassium concentrations.
Example C
Measurement of Potassium Ion Concentration Using Pyruvate Kinase in the Presence of a Sodium Ion-Binding Agent.
As for Example B, but human serum albumin is omitted and the medium contains in addition 6 μmol of Kryptofix® 221 per assay. A pH of 7.8 is selected to minimise variations in displacement of sodium ions from Kryptofix® 221 due to the differing potassium ion content of Individual specimens.
Example D
Measurement of Sodium Ion Concentration Using ß-D-galactosidase
Variation a: The final incubation mixture contains:
300 mmol/1 Tris HCl, pH 8.7 (37°C)
4 mmol/1 Dithiothreitol
7.5 mmol/1 Magnesium sulphate
16 mmol/1 Lithium chloride
0.44 mmol/1 EGTA (lithium salt)
460 mg/1 Human Serum Albumin
760 U/1 ß-Galactosidase
1.5 mmol/1 NPG
1.25 μmol/assay Kryptofix® 221
The reaction is monitored at 420 nm (or nearby) wavelength to determine the rate of formation of free 2-nitrophenol and hence the concentration of sodium ions in the original sample.
Variation b: An alternative approach compared with Variation a would be to reduce the sample concentration ten-fold by pre-dilution or to use a small sample volume, in which case the cryptand could be omitted.
Variation c: Measurement in fluids of low sodium ion content (e.g. <20 mmol/1) in which case the cryptand could be omitted.
Example E
Measurement of Sodium Ions with Pyruvate Kinase (Direct Stimulation of Enzyme Activity by Sodium Ions, under conditions where sensitivity of potassium ions is diminished).
Variation a: Incubation mixture contains for a 10 ul plasma sample:
300 mmol/1 Tris HCl, pH 8.7 (37°C)
5 mmol/1 MgCl2
2.6 mmol/1 ADP (free acid)
2.9 mmol/1 PEP (neutralized Tris salt)
0.34 mmol/1 NADH
17 000 U/1 LDH (assayed at 25°C)
2 000 U/1 PK (from rabbit muscle, assayed at 37°C)
4 mmol/1 KG
8 600 U/1 GDH in glycerol (assayed at 25°C)
1.25 μmol/assay Kryptofix® 222
Sodium ion calibrating solutions contain 4 mmol/1 potassium to compensate for the potassium activating effect of serum potassium ions on pyruvate kinase.
E xamp le F
Measurement of Sodium Ions with Pyruvate Kinase (Competitive Binding Assay) - Potassium Ion Concentration Known
The final incubation mixture contains for a 10 μl plasma sample:
300 mmol/1 Glycine, pH 9.8
5 mmol/1 MgCl2
2.6 mmol/1 ADP (free acid)
2.9 mmol/1 PEP (neutralized tris salt)
0.34 mmol/1 NADH
17 000 U/1 LDH (assayed at 25°C)
890 U/1 PK from Rabbit muscle (assayed at 37°C)
4 mmol/1 KG
8 500 U/1 GDH (assayed at 25°C)
5 mmol/1 KCl
2.5 μmol/assay Kryptofix® 221
Potassium chloride is added to this reagent and displaced stoichiometrically from Kryptofix® 221 by sodium ions, thus allowing the sodium ion concentration of the specimen to be quantified.
Example G
Measurement of Potassium and Sodium Ion Concentration in the Same Cuvette (Twin-Test)
Sodium ion concentration is assayed first as in Example D except that the assay also contains:
2.6 mmol/1 ADP (free acid)
2.9 mmol/1 PEP (neutralized Tris salt)
0.4 mmol/1 NADH
4.0 mmol/1 KG
8 600 U/1 GDH
Following the measurement of sodium ions by means of determination fo the reaction rate, the pH of the incubation mixture is lowered to pH 7.4 with a hydrochloric acid aliquot.
Then the following ingredients are added to achieve the final concentrations indicated:
17 000 U/1 LDH
890 U/1 PK from Bacillus stearothermophilus
3.0 mmol/1 MnCl2
20.0 mmol/1 LiCl
The reaction rate may then be monitored at 340 nm but may also be measured at a slightly higher wavelength to minimise possible Interference by the 2-nitrophenol liberated in the sodium ion indicator reaction. E xampl e H
Measurement of Calcium Ion Concentration Using Calpain I
In this emoodiment, a small sample of blood is centrifuged to obtain plasma. For the measurement of calcium ions the sample was incubated with a mixture containing 50 mmol/1 imidazole-HCl buffer, pH 7.3, 5 mmol/1 L-cysteine, 2.5 mmol/1 2-mercaptoethanol, 0.1 mmol/1 EGTA and 5 mmol/1 Suc-Leu-Met-p-nitroanilide at 30°C. The increase of absorbance at 405 nm was monitored over at 5 min interval. The rate is proportional to the calcium ion concentration of the sample.
Example I
Measurement of chloride ion concentration using cathepsin C
In this embodiment a small sample of blood is centrifuged to obtain plasma (5μl). For the measurement of chloride ion the incubation mixture contains 0.05 mol/1 citrate buffer pH-5.0, 10mmol/1 cysteamine and 4 mmol/1 gly-arg-p-nitroanilide and 0.01 U/ml cathepsin C. The latter has been dialyzed against 10 mmol/1 sodiumphosphate buffer (pH - 6.8) and 43 % (v/v) of glycerol in order to remove chloride ions. A typical calibration curve obtained this way is shown in Fig. 1.
Example J
Measurement of chloride ion concentration using -amylase
Inhibition mixture contains for a 5 ul plasma sample:
Hepes or alternative chloride free buffer 100 mmol/1 pH 7.1 α-Amylase 600 U/1 α-Glucosidase 30 000 U/1
4,6-Ethylidene-G7PNP 5 mmol/1
The reaction is monitored at 405 nm (or nearby wavelength to determine the rate of formation of free 4-nitrophenol and hence the concentration of chloride ions in the original sample.
Measurement of bicarbonate ion concentration using
Variation a: The final incubation mixture contains:
5 mmol/1 Tris HCl, pH 7.8 (37°C) 4 mmol/1 Dithiothreitol 7.5 mmol/1 Magnesium sulphate 16 mmol/1 Lithium chloride 0.44 mmol/1 EGTA (lithium salt) 460 mg/1 Human serum albumin 1500 U/1 ß-Galactosidase 1.5 mmol/1 NPG 2.0 μmol/assay Kryptofix® 221 EGTA means Ethylenbis(oxyethylennitrilo)-tetraacetic acid. The sample is pre-incubated with an equivalent volume of HCl (for plasma, 75 mmol/1) to reduce sample pH to 4.5. The reaction is then monitored at 420 nm (or nearby) wavelength to determine the rate of formation of free 2-nitrophenol and hence to concentration of bicarbonate ions in the original sample. A correction is made for sodium ion concentration in the original specimen.
Variaton b: Pyridoxal kinase, pyridoxal and zinc ions are substituted for ß-galactosidase and NGP.

Claims

Patent claims
1. Process for the determination of ions in fluids, wherein the influence of these ions on the activity of an enzyme is measured.
2. Process as claimed in claim 1, wherein the fluid is a biological or non-biological fluid.
3. Process as claimed in claim 2, wherein the biological fluid is blood, serum, plasma, urine, sweat, cerebrospinal fluid, lymph or intestinal secretions, exudates or transudates and the non-biological fluid is water or an aqueous extract or mixture.
4. Process as claimed in one of the claims 1-3, wherein the enzyme is a transferase, a hydrolase, an oxidoreductase or a lyase.
5. Process as claimed in claim 4, wherein the transferase is transferring phosphorous containing groups and the hydrolase is a glycosidase or acting on peptide bonds.
6. Process as claimed in claim 5, wherein the hydrolase is α- or ß-D-galactosidase, carboxypeptidase A, collagenase, amylase, calpain I, calpain II, dipeptidyl aminopeptidase I (cathepsin C) or phosphoglycollate phosphatase.
7. Process as claimed in claim 5, wherein the transferase is pyruvate kinase, hexokinase, adenylate kinase, pyridoxal kinase or acetate kinase and the hydrolase is α- or ß-D-galactosidase or carboxypeptidase A.
8. Process as claimed in claim 4, wherein the oxidoreductase is acting on the CH-OH group of donor molecules or on the aldehyde or oxo group of donors.
9. Process as claimed in claim 7, wherein the oxidoreductase is glycerol dehydrogenase, acetaldehyde dehydrogenase or tyrosinase (catechol oxidase).
10. Process as claimed in claim 4, wherein the lyase is a carbon - carbon lyase or a carbon-oxygen lyase.
11. Process as claimed in claim 9, wherein the lyase is aldolase or carbonic anhydrase.
12. Process as claimed in one the claims 1-11, wherein the i on is potassium, sodium, calcium, magnesium, mangenese, lithium, lead, zinc, copper, iron or other heavy metals or non-metallic ions comprising protons, bicarbonate, chloride, ammonium or substances that give rise to ammonium.
13. Process as claimed in one of the claims 1-11, wherein interfering ions are masked with a binding agent.
14. Process as claimed in one of the claims 1-12, wherein the ion to be determined is reduced in concentration to optimal levels for measurement by means of a binding agent, if dilution of the sample is not feasible.
15. Process as claimed in one of the claims 1-14, wherein potassium ions are determined using pyruvate kinase, glycerol dehydrogenase or acetaldehyde dehydrogenase.
16. Process as claimed in claims 1-14, wherein sodium ions are determined by using the enzyme pyruvate kinase or ß-D-galactosidase.
17. Process as claimed in one of the claims 15 and 14, wherein the interfering ions or analytes are bound by cryptands, coronands, podands, crown ethers, spherands, hemispherands, calixarens and combinations thereof, natural occurring ionophores, cyclic peptides, complexones and chelating agents, and derivatives thereof, metals of the 1. and 2. side group of the periodic system.
18. Process as claimed in one of the claims 11-17, whereby in the determination of potassium ions the interfering sodium ions are bound by Kryptofix® 221 and in the determination of sodium ions the interfering potassium ions are bound by Kryptofix® 222.
19. Process as claimed in claim 14, whereby in the determination of sodium ions using ß-galactosidase the concentration of free sodium ions is reduced with a binding agent.
20. Process as claimed in claim 14, whereby the binding agent is Kryptofix® 221.
21. Process as claimed in claim 14, wherein the binding agents according to claim 17 are present, which form a complex with indicator ions and from which the indicator ions are displaced stoichiometrically by the ions which are to be determined analytes and wherein the influence of the displaced indicator ions on the activity of the enzyme is assayed, thereby giving an indirect measure of the concentration of the analytes.
22. Process as claimed in claim 21, wherein the enzyme is pyruvate kinase, the indicator ions are potassium, the binding agent is Kryptofix® 221 and the ion to be determined is sodium.
23. Process as claimed in claim 21, wherein the enzyme is a kinase, the indicator ion is Mg2+, the binding agent is a chelating agent and the ion is a metal.
24. Process as claimed in claim 25, wherein the enzyme is pyridoxal kinase, the indicator ion is Zn2+, the binding agent is
Kryptofix® 221 and the ion is a heavy metal.
25. Process as claimed in claim 21 whereby the ions to be measured cause a change in the pH value which displaces the indicator ions from a complex with a pH-sensitive binding agent.
26. Process as claimed in claim 25 wherein the enzyme is ß-galactosidase, the pH-sensitive binding agent is Kryptofix® 221, the indicator ions are sodium, and the ion to be mesured is bicarbonate.
27. Process as claimed in one of the claims 14 and 17, wherein the enzyme is α-amylase or cathepsin C, the binding agent is Ag or Hg and the ion to be determined is chloride.
28. Process as claimed in in one of the claims 14 and 17, wherein the enzyme is collagenase or calpain I or calpain II, the binding agent is a chelating agent and the ion to be determined is calcium.
29. Process as in claims 1-13, wherein ions which are competitive inhibitors of the sensitive indicator enzyme are included in the assay.
30. Process as claimed in claim 29, wherein the ions to be determined are sodium or potassium and the competitive inhibitor is lithium ion.
31. Composition for the determination of ions in fluids comprising an enzyme, the activity of which is influenced by the ion.
52. Composition for the determination of ions in fluids as claimed in claim 31, comprising an enzyme, the activity of which is influenced by the Ion, and a binding agent which binds the interfering ions in the fluid or lowers the concentration of analyte ions to optimal levels for measurement.
53. Composition as claimed in claim 32 for the determination of potassium ions comprising pyruvate kinase and a cryptand.
34. Composition as claimed in claim 35, wherein the cryptand is Kryptofix® 221.
35. Composition as claimed in claim 32 for the determination of sodium ions comprising pyruvate kinase and a cryptand.
36. Composition as claimed in claim 35, wherein the cryptand is Kryptofix® 222.
37. Composition as claimed in claim 32 for the determination of sodium ions comprising ß-D-galactosidase and a cryptand.
38. Composition as claimed in claim 37 wherein the cryptand is Kryptofixi® 221.
39. Composition as claimed in claim 31 comprising:
PK (B. stearothermophilus 50 U/1 to 10 000 U/1 PEP (neutralized Tris salt) 0.3 mmol/1 to 50 mmol/1
Kryptofix® 221 0 mmol/1 to 30 mmol/1 NADH 0.01 mmol/1 to 0.8 mmol/1 buffer, pH 7-8 50 mmol/1 to 500 mmol/1
Mn2+ or Mg2 +
1 mmol/1 to 10 mmol/1
LICl 2 mmol/1 to 100 mmol/1
ADP (free acid) 0.5 mmol/1 to 10 mmol/1
LDH (assayed at 25°C) 5 1 300 U/1 to 100 1 300 U/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25°C) 2 500 U/1 to 20 000 U/1 KG (free acid) 1 mmol/1 to 10 mmol/1
40. Composition as claimed in claim 31 comprising:
Glycerol dehydrogenase 50 U/1 to 1000 U/1
Glycerol 0.3 mol/1 to 3 mol/1 Kryptofix® 221 0 mmol/1 to 30 mmol/1
NAD 0.1 mmol/1 to 5.0 mmol/1 buffer, pH 9 20 mmol/1 to 500 mmol/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25 °C) 2 500 U/1 to 20 000 U/1
KG (free acid) 1 mmol/1 to 10 mmol/1
41. Composition as claimed in claim 31 comprising:
Acetaldehyde dehydirogenase 50 U/1 to 10 000 U/1
Glycolaldehyde 0.3 mmol/1 to 50 mmol/1
Kryptofix® 221 0 mmol/1 to 30 mmol/1
NAD 0.05 mmol/1 to 2.0 mmol/1 buffer, pH 7-8 50 mmol/1 to 500 mmol/1
Dithiothreitol 0.1 mmol/1 to 2 mmol/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25ºC) 2 -500 U/1 to 20 000 U/1
KG (free acid) 1 mmol/1 to 10 mmol/1
42. Composition as claimed in claim 31 comprising:
Acetaldehyde dehydrogenase 50 U/1 to 10 000 U/1
4-nitrophenyl acetate 0.1 mmol/1 to 2 mmol/1
Kryptofix® 221 0 mmol/1 to 30 mmol/1
NADH 0.001 mmol/1 to 0.1 mmol/1 buffer, pH 7-8 50 mmol/1 to 500 mmol/1
Dithiothreitol 0.1 mmol/1 to 2.0 mmol/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25ºC) 2 500 U/1 to 20 000 U/1
KG (free acid) 1 mmol/1 to 10 mmol/1
43. Composition as claimed in claim 51 comprising:
ß-D-galactosidase 25 U/1 to 7500 U/1 NPG 0.25 mmol/1 to 5 mmol/1
Kryptofix® 221 0 mmol/1 to 10 mmol/1 buffer, pH 7-9.5 200 mmol/1 to 500 mmol/1
Mg2+ 0.01 mmol/1 to 10 mmol/1
EGTA (Lithium salt) 0 mmol/1 to 20 mmol/1
Serum albumin 0 g/1 to 5 g/1
44. Composition as claimed in claim 31 comprising:
PK (rabbit muscle) 50 U/1 to 10 000 U/1 PEP (neutralized Tris salt) 0.3 mmol/1 to 30 mmol/1
Kryptofix® 221 1 mmol/1 to 10 mmol/1
NADH 0.01 mmol/1 to 0.8 mmol/1 buffer, pH 9-10 50 mmol/1 to 500 mmol/1
Mg2+ 1 mmol/1 to 10 mmol/1
ADP (free acid) 0.5 mmol/1 to 10 mmol/1
LDH (assayed at 25°C) 5 000 mmol/1 to 100 000 U/1
KCl 2 mmol/1 to 10 mmol/1
Serum albumin 0 g/1 to 5 g/1
GDH (assayed at 25°C) 2 500 U/1 to 20 000 U/1
KG (free acid) 1 mmol/1 to 10 mmol/1
45. Composition as claimed in claim 31 comprising:
Calpain I 1 000 U/1 to 40 000 U/1
Suc-Leu-Met-p-nitroanilide 1 mmol/1 to 20 mmol/1
Chelator 0.01 mmol/1 to 1 mmol/1
L-Cysteine 1 mmol/1 to 10 mmol/1
2-Mercaptoethanol 1 mmol/1 to 10 mmol/1
Buffer Imidazole-HCl 10 mmol/1 to 100 mmol/1 pH 6 - 8 (preferred range 7-7.5)
46. Composition as claimed in claim 31 comprising:
Hepes or alternative chloride free buffer 0.01-0.5 mmol/1 pH 6.5-7.5 α -amylase 60-6000 U/1 α-glucosidase 5000-300 000 U/1
4,6-ethylidene-G7PNP 0.5-10 mmol/1
47. Composition as claimed in claim 31 comprising:
citrate buffer 0.01 - 0.2 mol/1 pH 4 - 7 (preferred: 5.0 - 5.5) cysteamine 1 - 20 mmol/1 gly-arg-p-nitroanilide 1 - 20 mmol/1 cathepsin C 2 - 100 mU/ml
48. Composition as claimed in claim 31 comprising:
β-D-galactosidase 250 U/1 to 7500 U/1
NPG 0.25 mmol/1 to 5 mmol/1 Kryptofix® 221 0.2 mmol/1 to 5 mmol/1 buffer, pH 7.5-7.8 1 mmol/1 to 10 mmol/1 Mg2+ 0.01 mmol/1 to 10 mmol/1
EGTA (Li salt) 0.1 mmol/1 to 5 mmol/1 Serum albumin 0 g/1 to 5 g/1
EP88903229A 1987-04-10 1988-04-02 Determination of ions in fluids Pending EP0309525A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPI136587 1987-04-10
AU1365/87 1987-04-10
AU2311/87 1987-06-05
AUPI231187 1987-06-05

Publications (1)

Publication Number Publication Date
EP0309525A1 true EP0309525A1 (en) 1989-04-05

Family

ID=25643255

Family Applications (9)

Application Number Title Priority Date Filing Date
EP19920106025 Withdrawn EP0494705A3 (en) 1987-04-10 1988-04-02 Determination of ions in fluids
EP92106024A Withdrawn EP0508388A1 (en) 1987-04-10 1988-04-02 Method and composition for the determination of bicarbonate ions in fluids
EP91118973A Expired - Lifetime EP0470652B1 (en) 1987-04-10 1988-04-02 Method and composition for the determination of sodium ions in fluids
EP91118956A Expired - Lifetime EP0476715B1 (en) 1987-04-10 1988-04-02 Method and composition for the determination of chloride ions in fluids
EP19920106023 Withdrawn EP0494704A3 (en) 1987-04-10 1988-04-02 Method and composition for the determination of calcium ions in fluids
EP91118957A Expired - Lifetime EP0471391B1 (en) 1987-04-10 1988-04-02 Determination of ions in fluids
EP88105339A Expired - Lifetime EP0286039B1 (en) 1987-04-10 1988-04-02 Determination of potassium ions in fluids
EP92106026A Withdrawn EP0504948A1 (en) 1987-04-10 1988-04-02 Determination of ions in fluids
EP88903229A Pending EP0309525A1 (en) 1987-04-10 1988-04-02 Determination of ions in fluids

Family Applications Before (8)

Application Number Title Priority Date Filing Date
EP19920106025 Withdrawn EP0494705A3 (en) 1987-04-10 1988-04-02 Determination of ions in fluids
EP92106024A Withdrawn EP0508388A1 (en) 1987-04-10 1988-04-02 Method and composition for the determination of bicarbonate ions in fluids
EP91118973A Expired - Lifetime EP0470652B1 (en) 1987-04-10 1988-04-02 Method and composition for the determination of sodium ions in fluids
EP91118956A Expired - Lifetime EP0476715B1 (en) 1987-04-10 1988-04-02 Method and composition for the determination of chloride ions in fluids
EP19920106023 Withdrawn EP0494704A3 (en) 1987-04-10 1988-04-02 Method and composition for the determination of calcium ions in fluids
EP91118957A Expired - Lifetime EP0471391B1 (en) 1987-04-10 1988-04-02 Determination of ions in fluids
EP88105339A Expired - Lifetime EP0286039B1 (en) 1987-04-10 1988-04-02 Determination of potassium ions in fluids
EP92106026A Withdrawn EP0504948A1 (en) 1987-04-10 1988-04-02 Determination of ions in fluids

Country Status (24)

Country Link
US (1) US6068971A (en)
EP (9) EP0494705A3 (en)
JP (8) JPH0642839B2 (en)
KR (4) KR920010313B1 (en)
CN (3) CN1051111C (en)
AR (1) AR241802A1 (en)
AT (4) ATE148793T1 (en)
BR (1) BR8806575A (en)
CS (2) CS170892A3 (en)
DD (1) DD269919A5 (en)
DE (6) DE3881931D1 (en)
DK (1) DK687488D0 (en)
ES (4) ES2058165T3 (en)
FI (3) FI885727A0 (en)
HR (1) HRP940731A2 (en)
HU (5) HU9201057D0 (en)
IE (3) IE940436L (en)
IL (3) IL101585A (en)
LV (1) LV11068B (en)
NO (3) NO176072C (en)
NZ (3) NZ239095A (en)
RU (1) RU2054674C1 (en)
WO (1) WO1988008137A1 (en)
YU (1) YU47192B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766870A (en) * 1993-08-23 1998-06-16 Kyowa Medex Co., Ltd. Method of quantitative determination of sodium ions

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274343A1 (en) * 1987-01-06 1988-07-13 IntraCel Corporation A system of reactants involving an apo-enzyme useful in immunological analysis and a method for carrying out immunoassays with this system
EP0494705A3 (en) * 1987-04-10 1992-09-02 The Flinders University Of South Australia Determination of ions in fluids
US5013648A (en) * 1988-09-09 1991-05-07 Em Diagnostic Systems, Inc. Enzymatic detection of monovalent anions
JP2748134B2 (en) * 1988-11-29 1998-05-06 オリエンタル酵母工業株式会社 Determination of magnesium
GB9015683D0 (en) * 1990-07-17 1990-09-05 Amersham Int Plc Testing for metal ions
JPH06508760A (en) * 1991-07-11 1994-10-06 ユニバーシテイ・オブ・メリーランド・アト・ボルチモア Lead assay method
US5334507A (en) * 1991-09-20 1994-08-02 Toyo Boseki Kabushiki Kaisha Composition for measurement of potassium ion concentration and composition for elimination of ammonium ions
DE69226940T2 (en) * 1991-12-02 1999-05-27 Oriental Yeast Co Ltd Method and reagent for the determination of serum iron or the binding ability of unsaturated iron by using aconitase
EP0702088A4 (en) * 1993-04-07 1998-04-29 Kyowa Medex Co Ltd Method of determining sodium ion
JPH06311896A (en) * 1993-04-30 1994-11-08 Kyowa Medex Co Ltd Determination of potassium ion
US5532136A (en) * 1993-06-22 1996-07-02 Bionebraska, Inc. Monoclonal antibody assay and kit for detecting metal cations in body fluids
DE4401868C1 (en) * 1994-01-22 1995-02-16 Lobbe Xenex Gmbh Microbial method for detecting pollutants
JPH07203991A (en) * 1994-01-24 1995-08-08 Kyowa Medex Co Ltd Quantitative determination of potassium ion
US6114134A (en) * 1997-06-25 2000-09-05 International Reagents Corporation Method for assaying biological specimens for substances contained in the components thereof and reagent to be used in this method
DE69840725D1 (en) * 1997-06-25 2009-05-20 Sysmex Corp METHOD AND REAGENTS FOR DETERMINING SUBSTANCES IN BIOLOGICAL SAMPLES
JP4416866B2 (en) * 1998-07-30 2010-02-17 オリエンタル酵母工業株式会社 Liquid reagent for calcium measurement
AU5781800A (en) * 1999-07-06 2001-01-22 General Atomics Methods and compositions for assaying analytes
US7192729B2 (en) 1999-07-06 2007-03-20 General Atomics Methods for assaying homocysteine
US6376210B1 (en) 1999-07-06 2002-04-23 General Atomics Methods and compositions for assaying analytes
US6610504B1 (en) 2000-04-10 2003-08-26 General Atomics Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
US7045098B2 (en) 2001-02-02 2006-05-16 James Matthew Stephens Apparatus and method for removing interfering substances from a urine sample using a chemical oxidant
US20030022390A1 (en) * 2002-05-30 2003-01-30 Stephens James Matthew Method and kit for making interfering substances in urine undetectable
US6811997B2 (en) * 2002-07-02 2004-11-02 Bechtel Bwxt Idaho, Llc Method for chromium analysis and speciation
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US7384760B2 (en) 2004-04-30 2008-06-10 General Atomics Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase
US8170803B2 (en) 2004-07-13 2012-05-01 Dexcom, Inc. Transcutaneous analyte sensor
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor
EP1784162A2 (en) * 2004-08-23 2007-05-16 Remote Clinical Solutions, Inc. System and method for modifying a fluid for oral administration
US20060121548A1 (en) * 2004-11-09 2006-06-08 Remote Clinical Solutions, Inc. Systems and methods for measuring sodium concentration in saliva
US20070015287A1 (en) * 2005-07-15 2007-01-18 Remote Clinical Solutions, Inc. Methods and devices for measuring analyte concentration in a nonblood body fluid sample
JP2007116977A (en) * 2005-10-27 2007-05-17 Toyobo Co Ltd Method for reducing effect to other measurement item
CN100458420C (en) * 2006-12-21 2009-02-04 中电投远达环保工程有限公司 Method for measuring chlorion in lime slurry by nitric acid mercurimetry
WO2008151208A1 (en) * 2007-06-04 2008-12-11 Lehigh University Rapid sensing of toxic metals with hybrid inorganic materials
WO2009020782A2 (en) * 2007-08-06 2009-02-12 Oft Labs Llc Oral fluid assays for the detection of heavy metal exposure
WO2009079120A1 (en) * 2007-12-14 2009-06-25 Genewiz Inc. Methods for measuring adp
WO2009135035A1 (en) * 2008-05-02 2009-11-05 Specialty Assays, Inc. Enzymatic determination of potassium ions using stable nad(p)h analogs.
CA2794386C (en) 2010-03-30 2015-09-01 F. Hoffmann-La Roche A.G. Method for measurement of calcium ions
CN102539696A (en) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 Determination method of ammonia (ammonium ion) and diagnosis/determination reagent kit of ammonia (ammonium ion)
CN102539682A (en) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 Determination method of ammonia (ammonium ion) and diagnosis/determination reagent kit of ammonia (ammonium ion)
JP5100903B1 (en) * 2012-04-06 2012-12-19 Ａｋｊグローバルテクノロジー株式会社 Lithium reagent composition, lithium ion measuring method and measuring apparatus using the same
JP5222432B1 (en) * 2012-11-07 2013-06-26 Ａｋｊグローバルテクノロジー株式会社 Lithium measurement method
KR101506147B1 (en) * 2013-12-13 2015-03-26 삼성전자 주식회사 Reagent set, test method of sample, microfluidic device and test apparatus
RU2569172C1 (en) * 2014-05-05 2015-11-20 Федеральное государственное бюджетное учреждение науки Институт высокотемпературной электрохимии Уральского отделения Российской Академии наук Method for determining proton concentration in proton-conducting oxide materials
CN105420344A (en) * 2015-12-12 2016-03-23 山东博科生物产业有限公司 Stable serum-potassium detection reagent with high anti-interference capability and detection method
US11214821B2 (en) 2016-07-18 2022-01-04 Vision Diagnostics, Inc. Reagents and methods of use with automated analyzers for obtaining a specific gravity index for urine
RU2630695C1 (en) * 2016-12-14 2017-09-12 Федеральное государственное бюджетное учреждение науки Институт физической химии и электрохимии им. А.Н. Фрумкина Российской академии наук (ИФХЭ РАН) 2,4,6-tris[(2-diphenylphosphoryl)-4-ethylphenoxy]-1,3,5-triazine as electrode-active selective ionophore for lithium cation in plasticised membranes of ion-selective electrodes
CN108607237B (en) * 2018-05-03 2019-06-21 大连理工大学 A kind of guard method of ADP aglucon chromatography media
CN109187522A (en) * 2018-08-31 2019-01-11 山东博科生物产业有限公司 A kind of serum sodium colorimetric determination kit
EP3864167A4 (en) * 2018-10-12 2022-11-23 Polymer Technology Systems, Inc. Systems and methods for point-of-care detection of potassium
CN111208176B (en) * 2020-01-15 2022-11-08 湖南工业大学 Electrochemical test strip for detecting potassium ion and sodium ion concentrations and detection method thereof
CN113718015A (en) * 2021-08-27 2021-11-30 迪瑞医疗科技股份有限公司 Preparation method of in-vitro enzyme method potassium determination kit

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH316613A (en) * 1950-02-25 1956-10-15 Security Trust Company Of Roch Process for preparing an indicator compound based on ion exchange resin
US2791533A (en) * 1951-02-24 1957-05-07 Security Trust Company Ion exchange resin indicator compound
DE2137146B2 (en) 1971-07-24 1974-07-04 C.H. Boehringer Sohn, 6507 Ingelheim Method for the photometric determination of chloride ions in body fluids
DE2349819A1 (en) * 1973-10-04 1975-04-17 Eppendorf Geraetebau Netheler PROCEDURE FOR THE ENZYMKINETIC CONCENTRATION OF A SUBSTRATE
JPS5414196A (en) * 1977-07-05 1979-02-02 Taiko Electric Works Ltd Automatic posting device input expansion system
JPS56164787A (en) * 1980-05-21 1981-12-17 Unitika Ltd Production of heat-resistant pyruvate kinase
US4278440A (en) 1980-02-04 1981-07-14 Union Carbide Corporation Reagent and method for direct determination of chloride in serum
US4734375A (en) * 1980-05-27 1988-03-29 Miles Laboratories, Inc. Ion specific test method
CA1168705A (en) * 1980-05-27 1984-06-05 Hamish Small Ion exchange chromatography with indirect photometric detection
EP0076478B1 (en) * 1981-10-05 1986-01-15 Boehringer Mannheim Corporation Linear kinetic determination of bicarbonate in body fluids
DE3202779A1 (en) * 1982-01-28 1983-08-04 Merck Patent Gmbh, 6100 Darmstadt POTASSIUM REAGENT AND METHOD FOR DETERMINING POTASSIUM IONS
US4393142A (en) 1982-02-01 1983-07-12 American Monitor Corporation Assay method and reagent for the determination of chloride
US4455371A (en) * 1982-03-03 1984-06-19 The Ohio State University Research Foundation Oxalate oxidase composition for assay of oxalate
US4663278A (en) * 1982-04-30 1987-05-05 Syva Company Agglutination dependent enzyme channeling immunoassay
US4657854A (en) * 1983-05-05 1987-04-14 Ivan Endre Modrovich Assay systems based on magnesium-responsive enzymes
CA1222438A (en) * 1983-05-12 1987-06-02 Steven C. Charlton Unified test means for ion determination
DE3345748A1 (en) 1983-12-17 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim PHENOLSULPHONPHTHALEINYL-SS-D-GALACTOSIDE, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR DETERMINING THE SS-D-GALACTOSIDASE
EP0150227A1 (en) * 1983-12-23 1985-08-07 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Dipeptide derivatives and their use in determining the activity of carboxypeptidase A
DE3411574A1 (en) 1984-03-29 1985-10-10 Boehringer Mannheim Gmbh, 6800 Mannheim GLYCOSIDES OF RESORUFIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR DETERMINING THE ACTIVITY OF GLYCOSIDASES
JPS61151460A (en) * 1984-12-25 1986-07-10 Fuji Photo Film Co Ltd Integral type multi-layered analysis element for analysis of calcium or magnesium
DD236114A1 (en) * 1985-04-09 1986-05-28 Univ Halle Wittenberg METHOD FOR DETERMINING BACTERIAL INFECTION IN LIQUORES
DE3614470A1 (en) * 1985-05-02 1986-11-20 Gary D. Flushing N.Y. Steinman Method for measuring the potassium contents in biological fluids
CA1272941C (en) * 1985-07-02 1990-08-21 Multilayer ion test means
JPS6236199A (en) * 1985-08-07 1987-02-17 Kyowa Hakko Kogyo Co Ltd Method of determining calcium ion
JPH0612999B2 (en) * 1986-11-17 1994-02-23 関東化学株式会社 Chloride ion determination reagent
US4820647A (en) * 1986-12-03 1989-04-11 Biotrack, Inc. Method for detecting a metal ion in an aqueous environment
GB8708034D0 (en) * 1987-04-03 1987-05-07 British Telecomm Optical fibre device fabrication
EP0494705A3 (en) * 1987-04-10 1992-09-02 The Flinders University Of South Australia Determination of ions in fluids
US5384246A (en) * 1987-04-10 1995-01-24 Boehringer Mannheim Gmbh Determination of ions in fluids by a process involving displacement of indicator ions
US5162525A (en) * 1987-07-31 1992-11-10 Allied-Signal Inc. Fluorogenic and chromogenic three-dimensional ionophores as selective reagents for detecting ions in biological fluids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8808137A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766870A (en) * 1993-08-23 1998-06-16 Kyowa Medex Co., Ltd. Method of quantitative determination of sodium ions

Also Published As

Publication number Publication date
DE3881931D1 (en) 1993-07-29
NO885350L (en) 1988-11-30
KR890700833A (en) 1989-04-27
FI885727A (en) 1988-12-09
JPH05276994A (en) 1993-10-26
LV11068A (en) 1996-02-20
IE940436L (en) 1988-10-10
IL101585A0 (en) 1992-12-30
DK687488A (en) 1988-12-09
EP0471391B1 (en) 1997-02-05
EP0476715A3 (en) 1992-07-22
EP0494704A3 (en) 1992-09-02
CN1088109C (en) 2002-07-24
KR920010132B1 (en) 1992-11-16
ATE148793T1 (en) 1997-02-15
NZ239095A (en) 1994-10-26
EP0470652B1 (en) 1996-12-18
HU9201058D0 (en) 1992-06-29
CS170792A3 (en) 1992-12-16
IL101586A0 (en) 1992-12-30
CS170892A3 (en) 1992-12-16
JPH05276993A (en) 1993-10-26
JPH05130896A (en) 1993-05-28
AR241802A1 (en) 1992-12-30
KR920009425B1 (en) 1992-10-16
EP0504948A1 (en) 1992-09-23
IE940435L (en) 1988-10-10
JPH0564599A (en) 1993-03-19
KR920010312B1 (en) 1992-11-26
IE62537B1 (en) 1995-02-08
DK687488D0 (en) 1988-12-09
NO176072B (en) 1994-10-17
HUT51677A (en) 1990-05-28
FI942872A (en) 1994-06-16
IE881022L (en) 1988-10-10
HRP940731A2 (en) 1996-12-31
ES2097781T3 (en) 1997-04-16
NO932855L (en) 1988-11-30
EP0476715B1 (en) 1996-12-18
EP0286039B1 (en) 1993-06-23
ES2098300T3 (en) 1997-05-01
RU2054674C1 (en) 1996-02-20
ATE146599T1 (en) 1997-01-15
FI942873A0 (en) 1994-06-16
FI942872A0 (en) 1994-06-16
EP0470652A3 (en) 1992-07-29
JP3080770B2 (en) 2000-08-28
DD269919A5 (en) 1989-07-12
IL101586A (en) 1995-12-08
NO932856L (en) 1988-11-30
EP0470652A2 (en) 1992-02-12
KR910005411A (en) 1991-03-30
NZ239099A (en) 1994-10-26
IL86017A (en) 1995-12-08
FI942873A (en) 1994-06-16
WO1988008137A1 (en) 1988-10-20
NZ224171A (en) 1994-10-26
DE3855715T2 (en) 1997-05-07
JPH05130893A (en) 1993-05-28
KR920010313B1 (en) 1992-11-26
NO176072C (en) 1995-01-25
JPH05130895A (en) 1993-05-28
CN1051111C (en) 2000-04-05
DE3855715D1 (en) 1997-01-30
CN1096583A (en) 1994-12-21
EP0286039A2 (en) 1988-10-12
FI885727A0 (en) 1988-12-09
DE3855714T2 (en) 1997-05-07
IL101585A (en) 1995-12-08
JPH0642839B2 (en) 1994-06-08
HU9201057D0 (en) 1992-06-29
DE3890267T1 (en) 1989-05-03
EP0476715A2 (en) 1992-03-25
EP0471391A3 (en) 1992-12-09
NO932855D0 (en) 1993-08-11
DE3881931T2 (en) 1993-12-16
US6068971A (en) 2000-05-30
BR8806575A (en) 1989-10-31
JPH01503596A (en) 1989-12-07
ATE91025T1 (en) 1993-07-15
EP0471391A2 (en) 1992-02-19
LV11068B (en) 1996-04-20
NO932856D0 (en) 1993-08-11
ES2058165T3 (en) 1994-11-01
HU9201060D0 (en) 1992-06-29
CN1089808C (en) 2002-08-28
NO885350D0 (en) 1988-11-30
CN1104772A (en) 1995-07-05
JPH05130894A (en) 1993-05-28
YU69988A (en) 1990-02-28
DE3855790D1 (en) 1997-03-20
YU47192B (en) 1995-01-31
JP2610074B2 (en) 1997-05-14
EP0508388A1 (en) 1992-10-14
HU9201059D0 (en) 1992-06-29
EP0494705A2 (en) 1992-07-15
ATE146600T1 (en) 1997-01-15
DE3855714D1 (en) 1997-01-30
EP0494704A2 (en) 1992-07-15
EP0494705A3 (en) 1992-09-02
ES2097782T3 (en) 1997-04-16
CN1030094A (en) 1989-01-04
JP2683182B2 (en) 1997-11-26
DE3855790T2 (en) 1997-06-12
EP0286039A3 (en) 1988-12-28

Similar Documents

Publication Publication Date Title
US6068971A (en) Process for determination of ions in fluids by masking of interfering ions
US5384246A (en) Determination of ions in fluids by a process involving displacement of indicator ions
AU662510B2 (en) Determination of ions in fluids
AU622859C (en) Method and composition for the determination of potassium ions in fluids
AU662516B2 (en) Determination of ions in fluids
AU662515B2 (en) Determination of ions in fluids
AU662726B2 (en) Determination of ions in fluids
AU651712B2 (en) Determination of ions in fluids
AU622859B2 (en) Method and composition for the determination of potassium ions in fluids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19881112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 88105339.1/0286039 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 11.07.90.